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                                                                                                                                                                 Summary 
SUMMARY 
 
During the 20th century revolutionary breakthroughs in medicine were achieved: e.g. the 
advent of antibiotics and vaccinations have resulted in overcoming many infectious 
diseases. In contrast, a large number of genetic diseases remain with no effective treatment 
in place. These disorders are caused by inherited or spontaneous mutations that result in the 
absence or dysfunction of an indispensable gene product. Cure may require the 
reconstitution of the missing function through a molecular treatment approach. The aim of 
this study was to investigate two strategies for the molecular therapy of Duchenne muscular 
dystrophy (DMD), an X-linked fatal muscle wasting disease. Specifically, the muscle 
creatine kinase promoter as a muscle specific gene expression element for dystrophin gene 
therapy and the use of gentamicin to induce translational "read-through" of dystrophin point 
mutations were studied in detail (see below). This work provided important insights into 
possible treatment strategies for DMD, which may not only be helpful for future basic 
research projects but also for upcoming clinical trials. Additionally, these findings may not 
only apply to the therapy of DMD but also to the treatment of other genetic diseases such as 
cystic fibrosis or haemophilia. 
 
The strategy for gene therapy of DMD is to introduce an additional copy of the dystrophin 
gene/cDNA into skeletal muscle fibres to protect them from necrosis and to prevent their 
eventual loss that leads to muscle weakness. The most promising gene delivery vehicles, 
viral vectors, suffer from several limitations including immunogenicity, loss of therapeutic 
gene expression, and a limited packaging capacity. Therefore, various efforts were 
undertaken to use small therapeutic genes and to place them under the control of a strong 
and muscle-specific promoter. One aim of this study was to examine the effects of a mini-
dystrophin (6.3 kb) under the control of a short muscle-specific promoter (MCK 1.35 kb) 
over most of the lifetime (4-20 months) of a transgenic mouse model. 
  
Dystrophin expression remained stable and muscle-specific at all ages and greatly 
ameliorated the dystrophic phenotype. Importantly, muscle function in limb muscles was 
significantly improved not only in young but also in aged transgenic mice as compared to 
non-transgenic littermates. Interestingly, dystrophin expression was strong in fast-twitch 
skeletal muscles such as M. tibialis anterior and M. extensor digitorum longus but weak or 
absent in heart, diaphragm and slow-twitch muscles. Additionally, expression was strong in 
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glycolytic but weak in oxidative fibres of fast-twitch muscles. In conclusion, the MCK 
promoter may be well suited for certain applications which require long-lasting and strong 
muscle specific gene expression such as DNA-vaccination or the production of soluble 
proteins in muscle tissue for metabolic engineering. For the gene therapy of DMD and 
other muscular dystrophies, the MCK promoter may be most efficient in fast skeletal 
muscles but may not be adequate for use in tissues such as heart and diaphragm.   
 
An alternative strategy for the restoration of functional dystrophin is aimed at overcoming 
the deleterious mutation by interfering with protein translation. A recent report suggested 
that aminoglycoside antibiotics may restore the expression of functional dystrophin to 
skeletal muscles of mdx mice, the animal model of DMD. This raised hopes that DMD may 
be treatable by a conventional drug, and several clinical trials were initiated. The proposed 
mechanism relies on the ability of aminoglycosides to interfere with translation and thereby 
permitting “read-through” of premature stop codons. Therefore, we investigated the effect 
of gentamicin treatment on dystrophin expression and force generation. For in vitro 
experiments, an immortalised myogenic mdx cell line was established, and cells were 
treated with gentamicin. Additionally, mdx mice received direct gentamicin injections. We 
did neither detect significant “read-through”-effects nor positive effects on muscle 
histology and function by gentamicin treatment. Therefore, we believe that additional 
preclinical experimentation is required to further evaluate the possibility of in vivo 
aminoglycoside therapy of DMD or other diseases. 
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Part I 
         
 
 Background               
 
DUCHENNE MUSCULAR DYSTROPHY 
Duchenne muscular dystrophy (DMD) is a X-linked fatal progressive muscle wasting 
disease. With an incidence of ~ 1 in 3.500 male new-borns it is the most common muscular 
dystrophy and one of the most common fatal hereditary diseases. It was first described by 
Duchenne (Duchenne, 1868) and Gowers (Gowers, 1879). Affected boys appear normal at 
birth. First clinical symptoms of the disease develop between 2 and 5 years of age. They 
include a delay in walking, difficulties in climbing stairs and a waddling gait (Dubowitz, 
1978). A typical behavioural adaptation (Gowers´s sign) is that patients use the arms to 
“climb” up the own thighs,  when changing from a lying to a standing position. Calf 
muscles show a marked pseudohypertrophy while all proximal muscles become 
progressively weaker. On average the patients become confined to a wheelchair by the age 
of 12. Before mechanical ventilation was introduced, most DMD patients died from 
respiratory or cardiac failure in the second or third decade of life. Becker muscular 
dystrophy (BMD) is a milder allelic form of the disease (Becker and Kiener, 1955). Even 
though the clinical symptoms are similar to DMD they are significantly delayed. Some 
BMD patients remain ambulant until old age (England et al., 1990). Dystrophin is not only 
indispensable to guarantee muscle function, but also plays a role in the brain. This role is 
poorly understood presently, but absence of dystrophin in DMD may result in a mild 
cognitive impairment (Blake and Kroger, 2000; Mehler, 2000). Histological hallmarks of 
the disease in skeletal muscle are: fibre size variation, clusters of necrotic fibres, central 
nuclei in regenerating fibres, fibrosis, and infiltration of macrophages and CD4+ 
lymphocytes (Gorospe et al., 1990;  McDouall et al., 1990; Blake et al., 2002). The 
progressive nature of the disease results from the inability of the affected muscle to 
efficiently replace damaged muscle fibres. This is mainly due to an exhaustion of the 
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potential to regenerate fibres from muscle progenitor cells, in concert with the gradual 
replacement of muscle fibres by connective tissue (Reimann at al., 2000). A useful, 
although unspecific diagnostic marker even before the onset of a clinical phenotype is the 
strongly increased serum creatine phosphokinase activity. A definite diagnosis for DMD is 
based either on the absence of dystrophin protein in a muscle biopsy or on the molecular 
identification of a mutation in the dystrophin gene. About 65% of dystrophin mutations are 
large deletions and duplications which occur preferentially at two mutation “hot spots” 
(Koenig at al., 1989). The remaining mutations are evenly distributed over the whole gene: 
18% are nonsense mutations, 8% small deletions or insertions, 7% splice site mutations, 
and 2% are missense mutations (Roberts et al., 1994). According to the “reading frame 
theory” (Monaco et al., 1988) a deletion or duplication causing a frame shift leads to a 
premature termination of translation. The resulting dystrophin protein is truncated, not 
functional, and due to low mRNA and protein stability only present at very low levels. 
Patients with such mutations will develop DMD. Surprisingly, even these patients show a 
small subset of dystrophin positive fibres. The occurrence of so-called revertant fibres is 
directly associated with the nature of the mutation in individual patients. While some 
mutations allow revertant fibres others do not. A natural exon skipping mechanism was 
proposed to be the underlying molecular mechanism. Overall, revertant fibres are detected 
in approximately 50% of DMD patients and can account for 0.2 – 4 % of the total number 
of muscle fibres (Burrow et al., 1991; Nicholson et al., 1993).  
In BMD, the mutations usually cause the loss of a small, non-essential part of the molecule 
while the reading frame stays intact. This allows the expression of smaller dystrophin 
molecules. The resulting dystrophins can have varying degrees of functionality, depending 
on the size and the position of the deleted sequence. This is reflected by the wide spectrum 
of the clinical severity of BMD patients. Female carriers are not or only mildly affected 
because they are normally able to compensate the defect via the functional dystrophin copy 
on their second X chromosome. Current treatment options for DMD and BMD are very 
limited. No effective pharmacological treatment is available so far while supportive 
therapies like artificial ventilation have moderately prolonged patients’ survival but offer no 
cure (Scheuerbrandt, 1998).  
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DYSTROPHIN  
The molecular cause of DMD is a defect in a single gene located at Xp21 (Murray et al., 
1982). The dystrophin gene encompasses 2.4 Mb, contains 79 exons, and is one of the 
largest human genes (Coffey et al., 1992, Nobile et al., 1997). The full-length dystrophin 
protein has a molecular weight of 427 kDa and is translated from a 14kb mRNA. 
Expression is regulated by three independent promoters which have different activities e.g. 
in muscle and in brain (Boyce et al., 1991; Chelly et al., 1990; Klamut et al., 1990). These 
promoters use unique first exons which are spliced to the commonly used remaining 78 
exons. Four additional internal promoters express smaller dystrophin molecules which lack 
large N-terminal parts (Fig. 1-1).  
 
Fig. 1-1  Location of dystrophin promoters and organisation of functional domains. Three 
promoters (brain (B), muscle (M) and Purkinje neurones (P)) drive the expression of full-length 
dystrophin. Four additional internal promoters produce shortened dystrophins (Dp260, Dp140, 
Dp116, Dp71). The rod domain consists of 24 triple helical units and four hinge regions (H). 
Dystrophin contains a number of protein domains that form the binding sites for components of 
the dystrophin-associated protein complex. These are the WW domain (WW) the ZZ domain 
(ZZ) in the cysteine-rich region and the coiled-coil domain at the COOH Terminus (CT). 
(Adapted from Blake and Kroger, 2000.) 
 
The most common short dystrophin isoform is Dp71 (71 kDa) which is found in many non-
muscle tissues: e.g. in brain, lung, liver and kidney. However, Dp71 cannot replace full-
length dystrophin in skeletal muscle (Cox et al., 1994). The number of isoforms is further 
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increased through alternative splicing at the 3’-end which may regulate the binding of 
several dystrophin-associated proteins (Crawford et al., 2000).  
In skeletal muscle, dystrophin makes up approximately 0.002 % of the total protein and is 
located at the interior side of the sarcolemma. It is rod-shaped and contains 3685 amino 
acids which are organised into four different functional domains (Fig.1-1): the N-terminal 
actin-binding domain, the large rod domain, the cysteine-rich domain and the COOH-
terminal domain. The N-terminal domain has an actin-binding site (amino acids 1-220) 
whose crystal structure has been resolved in detail (Norwood et al., 2000) and which is 
homologous to the structures of α-actinin and β-spectrin. The rod domain (amino acids 
338-3,055) consists of 24 triple helical repeats of the spectrin type. These make up the 
majority of the total protein’s size and are responsible for its rod shape (Koenig et al., 
1988). It is believed that the rod domain acts as a spacer between the other domains. In 
addition to the repeat regions it contains four small proline-rich hinges which might confer 
some flexibility and a second actin-binding site (Rybakova et al., 1996; Koenig and 
Kunkel, 1990). The cystein-rich domain (amino acids 3,056-3,354) is crucial for the correct 
assembly of the complex of dystrophin-associated proteins. It contains several protein 
binding and regulatory motives: 1) A WW domain that binds proline rich substrates and is 
known from regulatory and signalling molecules (Bork and Sudol, 1994), 2) Two EF-hand 
motivs that resemble those in α-actinin and may bind intracellular Ca2+, 3) A ZZ motive 
that resembles zinc finger motives and was shown to bind calmodulin in a Ca2+ dependent 
manner (Ponting et al., 1996). The fourth domain of the dystrophin molecule is the COOH-
terminal region (amino acids 3,355-3,685). This region contains two α-helical coiled coil 
domains (Sadoulet-Puccio et al., 1997) and a region which is alternatively spliced in non-
skeletal muscle tissues such as brain and cardiac muscle.     
THE DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX 
In skeletal muscle, dystrophin is located at the cytoplasmatic site of the sarcolemma. 
Dystrophin binds to a complex of dystrophin-associated proteins (DAPC) which spans the 
sarcolemma. Together dystrophin and the DAPC provide a bridge between the extracellular 
matrix and the actin-based cytoskeleton. Dystrophin plays an essential part in the formation 
of the DAPC, because dystrophin deficiency leads to a loss of the DAPC. In the absence of 
dystrophin mRNA levels of DAPC components are normal, but the complex is not properly 
assembled and/or integrated into the sarcolemma or is degraded. A truncated dystrophin 
which contains the cysteine-rich domain, but not the N-terminal actin-binding site allows 
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the assembly of the DAPC. But importantly, when the restoration of the DAPC is mediated 
by this mutated dystrophin, the presence of the DAPC is not sufficient to prevent the DMD 
phenotype (Cox et al., 1994). This shows that both, the interaction with the DAPC and the 
connection to the actin-cytoskeleton via the actin-binding site are essential functions of the 
dystrophin molecule. The DAPC consists of three separate sub-complexes based on their 
localisation within the cell and their physical association with each other (Fig.1-2): the 
dystroglycan complex, the sarcoglycan complex and the cytoplasmatic complex (Blake et 
al., 2002).  
 
The two most important components of the dystroglycan complex are α- and β-
dystroglycan. They are both transcribed from a single dystroglycan gene and are 
subsequently proteolytically processed from a precurser protein (Ibraghimov-Beskrovnaya 
et al., 1993). α-dystroglycan is located on the extracellular site of the sarcolemma. It binds 
to several extracelluar matrix proteins like agrin or laminins. It is anchored to the 
membrane via a binding site to β-dystroglycan which has a single transmembrane domain 
and spans the sarcolemma. The COOH-terminus of β-dystroglycan binds to dystrophin. 
Crystal structure analysis of a β-dystroglycan/dystrophin complex revealed that β-
dystroglycan interacts with the WW domain and the EF-hands of dystrophin (Huang et al., 
2000). 
 
The sarcoglycan complex consists of five transmembrane proteins: α-, β-, γ- and δ-
sarcoglycan and sarcospan. The molecular interactions between the sarcoglycans and 
between them and the other components of the DAPC are not well understood. Mutations 
of the sarcoglycans are the cause of autosomal-recessive limb-girdle dystrophies (Straub 
and Campbell, 1997; Ozawa et al., 1998). 
 
The third component of the DAPC is the cytoplasmatic complex which contains the 
syntrophins and the dystrobrevins among other proteins. Five members of the syntrophin 
family (Piluso et al., 2000) of proteins are known: α1, β1, β2, γ1 and γ2. They are 
differentially expressed in different muscles, but all syntrophins share similar functional 
domains: a pleckstrin type PH-domain, a intact PH-domain, a syntrophin unique region and 
a PDZ-domain. The PDZ-domain interacts with several other proteins e.g. ErbB4, Na-
channels and nNOS (Brenman et al., 1996; Blake and Kroger, 2000).  
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Fig. 1-2 Organisation of the dystrophin-associated protein complex (DAPC) at the 
sarcolemma of skeletal muscle. Muscular dystrophies that result from mutations in different 
parts of the complex are indicated. Currently used animal models for the gene therapy of 
Duchenne muscular dystrophy are also shown. (Adapted from Allamand and Campbell, 2000) 
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The dystrobrevins are dystrophin-related proteins as they have significant sequence 
homology to the COOH-terminal part of dystrophin (Wagner et al., 1993; Roberts, 2001) . 
There are two independent dystrobrevin genes each encoding several isoforms (Sadoulet-
Puccio et al., 1996; Peters et al., 1997). α-dystrobrevins are expressed in muscle and the 
central nervous system while β-dystrobrevin is missing in muscle, but found in brain and 
other tissues, such as placenta and kidney. The exact function of α-dystrobrevins in skeletal 
muscle is unknown, but they may play a role in intracellular signal transduction.          
UTROPHIN  
Dystrophin and the dystrobrevins are not the only members of the dystrophin/dystrobrevin 
protein family. Vertebrates possess two other closely related proteins: utrophin and 
dystrophin-related protein 2 (Roberts et al., 1996). The utrophin gene is autosomally 
encoded (chromosome 6q24) and smaller than the dystrophin gene ~900 kb vs. 2,400 kb. 
Both genes share an almost identical intron-exon organisation, and it is very likely that they 
are paralogs that arose by duplication early in vertebrate evolution (Roberts and Bobrow, 
1998). 
The size and functional domain organisation of the two proteins are very similar. The 
utrophin protein has 3,433 amino acids and a molecular mass of 395 kDa. Most of the size 
difference to dystrophin results from a shorter rod-domain that contains 22 instead of 24 
repeats (dystrophin repeats 14 and 18 are missing in utrophin). Utrophin expression is 
regulated by several promoters (Burton et al., 1999; Dennis et al., 1996). The expression 
pattern of utrophin is different from dystrophin. Utrophin is generally more widely 
expressed, hence it’s name. It is found in non-muscle and in muscle cells. However, unlike 
dystrophin utrophin is not located at the sarcolemma, but at the neuromuscular and 
myotendinous junctions (Khurana et al., 1991). Utrophin knockout mice were normal 
except for reduced membran folding at the neuromuscular junction. Interestingly, 
dystrophin/utrophin double knockout mice showed a more severe phenotype (these mice 
die very prematurely at 20 weeks of age) than single knockout mice (Deconinck et al., 
1997; Grady et al., 1997). These data suggest that dystrophin and utrophin can compensate 
for each other. It was also shown that overexpression of utrophin in muscle prevents the 
dystrophic phenotype in dystrophin deficient mice (Tinsley et al., 1996; Tinsley et al., 
1998). Therefore, increased expression of utrophin at the sarcolemma may offer an 
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alternative therapeutic approach, and several strategies to achieve this goal are under 
development (Chaubourt et al., 1999; Corbi et al., 2000).  
FUNCTION OF DYSTROPHIN 
In depth studies of natural and intentionally induced mutations of dystrophin were 
undertaken to elucidate the function of the whole molecule, the functions of individual 
domains and interactions with other molecules. Because most gene therapy vectors have 
packaging size limitations for the therapeutic gene, a shortened dystrophin would be highly 
desirable. The size of dystrophin would need to be minimised without compromising 
functionality. Therefore, various experiments have been undertaken to answer the following 
question: what are the essential parts of the dystrophin protein and which parts might be 
dispensable and could be removed? The N-terminal domain and the cysteine-rich domain 
were shown to contain vital elements for optimal dystrophin function (Corrado et al., 1996). 
In contrast, the COOH-terminal region may be removed without major negative 
consequences (Rafael et al., 1996; Crawford et al., 2000) The region with the biggest 
potential for significant size reduction is the rod domain which makes up 74% of the full-
length molecule. Natural occurring large deletions of the rod domain were identified in 
BMD patients with very mild phenotypes (Love et al., 1991; Winnard, 1993; Mirabella et 
al., 1998). A shortened dystrophin with a large in-frame deletion in the rod-domain (exons 
17-48) based on a mutation found in such a patient was widely used in gene therapy trials 
(England et al., 1990). It is 46% shorter than the full-length dystrophin and is referred to as 
mini-dystrophin. In animal studies, it almost completely restored a normal muscle 
phenotype in the absence of full-length dystrophin (Cox et al., 1993; Wells et al., 1995). 
Recently, dystrophin constructs with even larger deletions in the rod domain and deletion of 
the COOH-terminus were developed (Harper et al., 2002; Scott et al., 2002). Some of these 
micro-dystrophins contained only four of the inverted terminal repeats. Their size was 
reduced by 74% when compared to full-length dystrophin. Even though micro-dystrophins 
correct most abnormalities related to dystrophin-deficiency, they do not restore full muscle 
strength. Therefore, the rod domain may not be completely removed to allow optimal 
function of dystrophin.  
 
Surprisingly, the exact role of dystrophin and the mechanisms by which its absence leads to 
the observed phenotype remain enigmatic. Several hypotheses have been proposed. And a 
10 
 
                                                                                                                               Background 
combination of different mechanisms may contribute to the pathogenesis including 
increased membrane permeability, elevated Ca2+ levels, proteolysis, oxidative damage, 
inflammation, apoptosis, regeneration, and fibrosis (Fig. 1-3).   
 
 
Fig. 1-3 The pathophysiology of Duchenne muscular dystrophy. Dystrophin deficiency 
results in the absence of the complex of dystrophin-associated proteins (DAPC). Muscle fibres 
become vulnerable to mechanical stress through the loss of mechanical stability and/or the loss 
of some so far unknown signalling capability. Increased membrane permeability, an impaired 
calcium homeostasis and activation of proteases contribute to increased levels of cell death. In 
the long term, insufficient regeneration and progressive fibrosis lead to an ultimately fatal 
muscle weakness. 
 
One of the crucial mechanisms shall be shortly discussed: Membranes of dystrophin 
deficient fibres have an increased permeability to macromolecules. This was shown in 
experiments where exogenous vital dyes such as Evans blue or Procion orange normally 
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excluded from muscle cells were internalised in dystrophin deficient cells (Bradley and 
Fulthorpe, 1978; Petrof et al., 1993; McArdle et al., 1994). 
This membrane permeability increases when the muscle is exercised. This may be an 
indicator of a structural weakness of the membranes which cannot withstand the physical 
forces which arise with muscle exercise. This idea is supported by several observations: 
heavy exercise leads to increased levels of muscle cell necrosis and infiltration of 
macrophages in muscles of DMD patients while inactivity reduces myonecrosis (Kimura et 
al., 1998). In the mouse model for DMD a susceptibility of muscles to contraction-induced 
stress was also observed. The first histological evidence of muscle damage in dystrophin-
deficient mice is found 2-3 weeks after birth when the mice start to move around to find 
there own food. In contrast, immobilisation or denervation of muscles prevents the 
development of muscle damage in mice.  
Alternatively a not yet identified signalling role of dystrophin together with the increased 
permeability may disrupt the normal balance of molecules inside and outside the cell. 
Elevated Ca2+ levels in muscle fibres of DMD patients may be of particular interest (Cullen 
and Fulthorpe, 1975). Calcium homeostasis plays an important regulatory role in muscle 
(Berchtold et al., 2000). Ca2+ levels may be increased not only by the increase in membrane 
permeability but also through leaky calcium channels (Carlson and Officer, 1996). 
ANIMAL MODELS FOR DMD 
Animal models have provided valuable clues to the understanding of DMD pathogenesis 
and offer good opportunities for the development and testing of therapeutic approaches 
(Allamand and Campbell, 2000). Several species of animals have been identified in which 
mutations in the dystrophin gene (murine, canine and feline) lead to the absence of 
dystrophin and to the development of dystrophy with varying degrees of severity. The mdx 
mouse (murine dystrophy x-linked) is the most common murine model for DMD. A point 
mutation in the dystrophin gene (position 3185) results in a premature stop codon (CAA -> 
TAA) (Sicinski et al., 1989). Skeletal muscle fibres are therefore dystrophin-negative with 
the exception of a small number of revertant fibres (about 1%). Surprisingly, the clinical 
phenotype in mdx mice is much more benign than in human DMD patients (Gillis, 1999). 
In captivity these animals have a nearly normal life expectancy and move normally at old 
ages. The reason for this marked difference in pathology between human and murine 
dystrophin deficiency is not understood. The mild phenotype of mdx mice leads to two 
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problems: firstly, it is more difficult to access the success of a therapeutic intervention, and 
secondly, one should be cautious to extrapolate results from mdx mice to human patients. 
Some features of DMD are also observed and can be evaluated in mdx mice. Creatine 
kinase activity levels are highly elevated. Necrosis-regeneration circles of muscle fibres 
start at 15-21 days of age and are still present in animals older than 2 years, peaking 
between the ages of 45 and 60 days. There is also a pronounced inflammatory reaction with 
invasion of immune cells into the muscle. Generally, some muscles are more affected than 
others. Histopathological signs and muscle force deficits are especially pronounced in 
diaphragm. On the contrary, in muscles which are composed mainly of fibres of small 
diameter such as extra-ocular muscles (Karpati and Carpenter, 1986) or smooth muscle 
(Boland et al., 1995) pathological signs are absent. A typical feature of regenerated muscle 
are centrally located nuclei. Under normal conditions nuclei return to the periphery of the 
muscle fibre after a regeneration process is completed. In mdx muscles very high levels of 
central nuclei were observed over the entire lifespan. It is not known why the nuclei remain 
central in mdx mice, but central nucleation is an easily measurable and well accepted 
indicator of muscle pathology in mdx mice.  
 
The dog model of DMD is golden retriever muscular dystrophy (GRMD). It is caused by a 
point mutation in the consensus splice acceptor site in intron 6 of the canine dystrophin 
gene. The mutation results in the deletion of exon from the mRNA thereby introducing a 
frame shift which leads to a premature stop codon. Affected pups gain weight slower than 
unaffected siblings. Hind limbs become increasingly affected and the animals often 
advance them simultaneously (bunny hopping). Many of the affected dogs die within days 
or months (Cooper et al., 1988). The severe clinical phenotype, the accompanying 
histopathological progression and the larger size of the animals make the GRMD dogs a 
good model for DMD (Howell et al., 1997; Cozzi et al., 2001). However limitations arise 
from observations that these dogs are difficult to breed and that there are large variations in 
the development of the phenotype e.g. some of the dogs live for 6 and more years. 
Hypertrophic feline muscular dystrophy (HFMD) has been described in dystrophin 
deficient cats (Carpenter et al., 1989; Gaschen and Burgunder, 2001). Hypertrophy is the 
most notable effect in affected animal. An abnormal gait and some necrosis are present but 
the overall phenotype is benign.   
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MOLECULAR THERAPY FOR DMD 
DMD is the most common fatal muscle disease and affects hundreds of thousands patients 
world-wide. Because no effective treatments are available, great efforts are underway to 
develop a cure. Once an effective approach is established it might be applicable with 
modifications in large numbers of other heritable diseases. Several different strategies could 
be envisioned for the treatment of DMD (Fig. 1-4).    
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One avenue for the successful treatment of DMD would be to substitute the defect 
dystrophin gene with a functional therapeutical gene. Methods for in vivo gene delivery to 
skeletal muscle fibres are either based on naked DNA transfer or on virally mediated gene 
transfer. High-level and long-lasting gene expression has been reached by the development 
of improved naked DNA transfer techniques: intravascular injections with high pressure 
(Budker et al., 1998), optimised electroporation conditions (Vicat et al., 2000) and use of 
ultrasound (Danialou et al., 2002). Several viral vector systems for gene therapy of muscle 
diseases are currently under development: adenovirus (Ad), adeno-associated virus (AAV) 
retroviruses, and herpes simplex virus (HSV). They all have distinct advantages and 
disadvantages which will be shortly discussed for the two most important vectors Ad and 
AAV.  
 
Ad vectors have a large cloning capacity, can be produced at high titers (1012-1013) and 
infect muscle fibres relative efficiently (Yang et al., 1998). The latest generation of Ad 
vectors are devoid of any viral sequences (Kochanek et al., 1996). This allows a maximal 
cloning capacity of >30 kb. It was envisaged that these “gutted” Ads will elicit a weaker 
immune response than earlier Ad vectors which still contain viral genes. Ad gene therapy 
vectors do not integrate into the genome of the target cells. This is an advantage because of 
safety considerations but it is unclear whether long term gene expression (> 1 year) can be 
achieved. 
 
AAV vectors hold great promise, because they infect muscle well, they show little 
immunogenicity, they can be produced at high titers (1012-1013) and they have the 
potential of site specific integration (Xiao et al., 1996; Fisher et al., 1997). Unfortunately, 
they have a relatively small packaging capacity of maximum 5 kb. It is not yet clear if 
micro-dystrophins of this size are completely functional (Harper et al., 2002).  
 
An alternative to the delivery of genes into muscle fibres is the transplantation of myogenic 
cells. These could be either myoblasts or myogenic stem cells. Myoblast therapy was 
already attempted in clinical trials, but the results were disappointing (Partridge et al., 
1998). It is hampered by the poor survival of the injected myoblasts. Only about 1% of the 
transplanted cells contribute to the formation of new muscle (Beauchamp et al., 1999). The 
poor survival is partly due to an immune response against the myoblasts and the therapeutic 
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protein (Guerette et al., 1997). Immunsuppresion of mdx mice has resulted in prolonged 
survival and even some functional improvement after myoblast transfer (Brussee, 1998). 
Recent advancements in stem cell research raised the hope that it might be possible to 
identify muscle progenitor cells that could not only be used for local injection but also for 
systemic application. Two reports describe that bone marrow transplantation of stem cells 
resulted in low level transgenic dystrophin expression in skeletal muscle (Bittner et al., 
1999; Gussoni et al., 1999). Clinical therapy of DMD would presumably require two steps 
prior to the application of the cells. Firstly, suitable stem cells would have to be isolated 
from the patient. And secondly, the therapeutic gene would need to be integrated into these 
stem cells. Lentiviral vectors could be used for this purpose because they efficiently infect a 
variety of stem cells (Van den Driessche et al., 2002). 
 
The goal of gene repair is not to replace the dysfunctional gene, but to allow the production 
of a functional protein through molecular manipulations which overcome a deleterious 
mutation. Therefore, this techniques will be limited to patients with mutations where all the 
functional domains of dystrophin are preserved, but the mutations prevent correct 
expression. It is estimated that up to 30-50% of DMD patients fall into this category. 
Depending on the nature of the mutation, one of the following strategies might be suitable: 
single base pair repair, targeted exon skipping or manipulations of the translation 
machinery.  
 
The repair of point mutations in the dystrophin gene has recently been demonstrated in 
cultured mdx cells and in muscles of mdx mice (Bertoni and Rando, 2002) This single base 
pair repair is mediated by so called chimeraplasts, which are single stranded RNA/DNA 
oligonucleotides. They bind in a first step to the targeted sequence and then in a second step 
trigger the repair of the mutation through the endogenous DNA repair machinery (Bartlett 
et al., 2000) In theory, this method would allow a permanent correction of all kinds of point 
mutations and therefore is a very general and promising approach. However, efficiencies 
have to be significantly improved because so far only 1-2% of all fibres per muscle were 
repaired which is not enough for clinical improvement.   
A different approach to overcome point mutations which introduce a premature stop codon 
is the manipulation of the translation machinery. This strategy will be examined in detail in 
Chapter IV. 
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Another possibility is using the mechanism of RNA-processing, e.g. to skip a stop codon 
mutation or to restore an open reading frame after a frame shift mutation. Even though the 
resulting proteins are predicted to be slightly smaller than the full-length dystrophin, they 
may nevertheless be highly functional, comparable to the functionality of Becker type 
dystrophins. A similar phenomenon occurs naturally in vivo: a small amount of dystrophin 
positive (revertant) fibres is regularly found in muscles of DMD patients. The exact 
mechanism of reversion is not understood, but a detailed study of revertant fibres in mdx 
muscle indicated that exon skipping was involved: several alternatively spliced dystrophin 
mRNA species were found which lacked the mdx premature stop codon in exon 23, while 
the stop codon could be still detected in the genomic dystrophin sequence of the dystrophin 
positive fibres (Wilton et al., 1997; Lu et al., 2000). To specifically induce exon skipping of 
mutations in DMD patients antisense oligonucleotides (AOs) were used. Successful 
skipping of the mdx stop codon (in exon 23 of the mouse dystrophin) mutation has already 
been demonstrated in vitro and in vivo when AOs specific for the junction of intron 22 and 
exon 23 were applied (Dunckley et al., 1998; Mann et al., 2001). 
 
An alternative to the repair of the mutated dystrophin or the transfer of a therapeutical gene 
is to upregulate a compensatory protein in affected cells. A natural candidate for such a 
purpose is the dystrophin paralog utrophin (Tinsley and Davies, 1993). Utrophin is already 
moderately upregulated in dystrophin deficient muscle. This upregulation was also detected 
in muscles of mdx mice. It was shown that utrophin can functionally replace dystrophin in 
numerous transgenic and viral-gene transfer studies (Tinsley et al., 1996; Wakefield et al., 
2000). To facilitate the improvement of utrophin expression in mature muscle fibres its 
regulatory elements were studied in great detail. This led to the discovery of a novel 
additional utrophin promoter (Burton et al., 1999). Large-scale screenings for small 
molecules that may specifically upregulate utrophin are currently under way.  
IMMUNE REACTIONS AGAINST TRANSGENE AND VECTOR 
Presently, immune reactions either against the vector system or the transgene itself are 
among the major obstacles which slow down the development of new therapies for DMD 
and genetic disorders in general. They can block or reduce the extent of gene transfer, 
hinder reapplication, result in the clearance of already cured cells, and cause systemic 
17 
 
                                                                                                                               Background 
reactions that in severe cases can lead to death (Yang et al., 1996; Morral et al., 2002). 
Several strategies may help to minimise these adverse immune reactions (Fig. 1-5).  
It is important to note that the dystrophin protein itself is potentially immunogenic in DMD 
patients. There is even concern that forced expression of “non-self” epitopes associated 
with therapeutic dystrophin may not only compromise long-term dystrophin expression, but 
even worsen muscle function by stimulating a cytotoxic T-cell mediated destruction of 
myofibres which express dystrophin (Ebihara et al., 2000). Depending on the kind and 
number of revertant fibres which might reduce dystrophin immunogenicity there might also 
be variations between different patients. Several studies reported an immune response in 
mdx mice against human dystrophin constructs (Ferrer et al., 2000; Braun et al., 2000). 
Another study showed that also murine dystrophin acted as a transplantation rejection 
antigen in mdx mice (Ohtsuka et al., 1998). One method to circumvent this problem may be 
the use of therapeutic utrophin constructs which are not immunogenic due to the normal or 
even increased utrophin expression in dystrophin deficiency. 
 
Fig. 1-5 Immune reactions and counter measures. 
 
The immune response against viral proteins of the vector may be very strong, but is usually 
transient, especially when AAV and gutted Ad vectors are used which contain no viral 
genes. Consequently there is no de novo viral protein synthesis and only for a short time the 
immune system is exposed to the viral proteins of the delivering viral vectors. Therefore, a 
transient immune suppression might be sufficient to avoid an immune response against the 
vector (Chamberlain, 2002).       
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The immune response can be divided in innate and acquired defense mechanisms. Innate 
immune responses are thought only to be directed against certain vectors and delivery 
routes (i.e. high doses of systemically injected adenoviral vectors) while not affecting other 
applications. Acquired immune responses can be differentiated in humoral (B-cell) and 
cellular (T-cell) pathways. A humoral immune response is based on circulating antibodies 
against newly introduced epitopes. While transgene persistence is normally not 
compromised by these antibodies, they can prevent successful readministration (Fisher et 
al., 2001). This problem may be circumvented by switching to different viral serotypes for 
successive administrations (Morral et al., 1999). The cellular immune response seems to be 
the main culprit responsible for the rapid declines of transgene expression in transfected 
muscle that has been observed in many gene transfer studies. The destruction of dystrophin- 
expressing cells in mdx mice is mediated through cytotoxic CD8+ cells. To become fully 
active, these cells require presentation of the antigen via the MHC I pathway. Because 
muscle fibres themselves only have low levels of MHC I and also lack important 
costimulatory molecules they require the help of professional antigen presenting cells e.g. 
dendritic cells for maximal activation of cytotoxic T cells. Ads readily infect macrophages 
and dendritic cells (Jooss et al., 1998). But AAV vectors (which have a low tropism for 
dendritic cells) evoked a cellular immune response against the transgene (Cordier et al., 
2000). It seems that the APCs receive antigen from transfected non-muscle cells or 
myofibres (Fig. 1-5) and then are able to present antigens on MHC I molecules via a cross-
priming pathway (Ulmer et al., 1996; Sarukhan et al., 2001). These effects may be avoided 
or diminished by the use of a muscle specific promoter which limits expression of the 
transgene to muscle cells. 
 
Not only the nature of the vector and the transgene influence the strength of the immune 
reaction but also the condition of the targeted muscle. The immunogenicity associated e.g. 
with AAV was more pronounced in dystrophic muscle than in normal muscle. In dystrophic 
muscles leaky or dying muscle fibres may release increased amounts of cytoplasmatically 
localised antigen and immune effector cells are present at elevated levels (Chamberlain, 
2002; Yuasa et al., 2002). 
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PART II 
 
Materials and Methods 
 
 
 
GENERATION OF DYSTROPHIN TRANSGENIC MDX MICE 
All animal experiments were conducted in accordance with recommendations of the 
institutional animal care committee and in agreement with provincial and federal law. A 
SacII/ClaI fragment from plasmid pAdMCKBecker (Larochelle et al., 2002) was 
microinjected into pronuclei of B6D2F2 zygotes using standard procedures (Hogan et al., 
1989). This fragment contains a previously described (Larochelle et al., 1997) short version 
of the MCK promoter and enhancer (1.35 kb; from nucleotide position –1354 to +1; 
transcription initiation site at np 0), a "Becker-type" mini-dystrophin with a large in-frame 
rod deletion (6.3kb), and the minimal rabbit beta-globin poly-A-signal (110 bp) (Jani et al., 
1997). DNA was extracted from mouse-tails, and founder animals were identified by PCR 
using the primer set: 5´-CCATGGGCAAACTGTAT and 5´-GGTAAGTTCTGTCCAAGC. 
After 2 min at 94°C the thermocycler was programmed for 3 cycles of 94°C x 1 min, 55°C 
x 1 min, 72°C x 2 min, then 30 cycles of 94°C x 50 s, 55°C x 50 s, 72°C x 50 s.  Primers 
correspond to dystrophin sequences adjacent to the 5'- and 3'- breakpoints of the large rod 
deletion. A 506 bp fragment is amplified from mini-dystrophin but not from full-length 
dystrophin.   
 
To ascertain whether the MCK promoter was integrated and intact in transgenic mice, a 1.6 
kb fragment was amplified from genomic DNA using the primers 5´-
CTGGTGCGGGTCTCATCGTA and 5´-CAGTCCTCTACTTCTTCCCA. After 2 minutes 
at 94°C the thermocycler was programmed for 35 cycles of 94°C x 1 min, 54°C x 2 min, 
72°C x 3 min. The primers correspond to transgene sequences that flank the 1.35 kb MCK 
promoter/enhancer; they do not amplify sequences from the endogenous MCK 
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promoter/enhancer. The 1.6kb PCR fragment was sequenced using additional internal 
primers. 
 
Breeding of the transgene onto the mdx background was established by crossing dystrophin 
transgenic male founders (F0) with mdx females. Transgenic male offspring (F1/N1) were 
bred with female mdx to generate male and female offspring (N2). These animals are 
negative for wild-type dystrophin and were used in the experiments described below. To 
eliminate any effects that might be due to minor differences in the genetic background, 
transgenic animals were always compared to non-transgenic littermates. 
DYSTROPHIN IMMUNOBLOTTING 
Frozen tissue samples were homogenised in RIPA buffer (Bulman et al., 1991). Protein 
concentration was determined using the BCA Protein Assay Reagent Kit (Pierce, Rockford, 
IL, U.S.A). Equal amounts of total protein were loaded onto 5.5% polyacrylamide gels and 
transferred to a nitro-cellulose membrane. Dystrophin expression was detected using an 
affinity-purified, polyclonal antiserum raised against 17 amino acids at the C-terminus of 
dystrophin (dilution 1:50; kindly provided by Dr. Paul Holland, Montreal) and visualised 
with anti-rabbit secondary antibody linked to horseradish peroxidase (Dianova, Hamburg, 
Germany; dilution 1:100) and chemiluminescence (Pierce).  This antiserum detects normal 
dystrophin (at approximately 420 kDa) as well as transgenic mini-dystrophin (at 
approximately 220 kDa).   
HISTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY 
Muscle samples were embedded in Tragacanth (Sigma, St Louis, MO) and frozen in 
melting isopentane. Serial cross sections (5 µm) were cut on a cryostate and used for 
staining. For dystrophin detection, a polyclonal antiserum was used (same as described 
under immunoblotting; dilution 1:50). Biotinylated secondary antibody (Dianova, 
Hamburg, Germany; dilution 1:100) was applied and visualised by Cy3-conjugated 
streptavidin (Dianova, Hamburg, Germany; dilution 1:1000). To visualise cell nuclei the 
sections were incubated with 12µg/ml bisbenzimide (Sigma, Taufkirchen, Germany) in 
PBS for 10 min. In a final step, sections were stained with the NADH-tetrazolium reductase 
method to distinguish between oxidative and glycolytic fibres: Sections were incubated for 
30 min at 37°C in 0.2 M Tris (pH 7.4), 1.5 mM NADH and 1.5 mM Nitroblue Tetrazolium 
(all from Sigma, Taufkirchen, Germany). After incubation, slides were rinsed 3 times with 
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distilled water. Fibre counts and determination of fibre area were performed using the 
UTHSCSA Image Tool program (University of Texas, Health Science Center, San Antonio, 
U.S.A.). Fibre scoring results are from seven M. tibialis anterior (TA) and M. extensor 
digitorum longus (EDL) muscles from 7 month-old MCK1.35 and mdx mice. For EDL, all 
fibres of an entire muscle cross-section were counted. For TA, five fields of 50-100 fibres 
were randomly chosen and evaluated. More than 300 fibres were scored for each TA and 
EDL muscle. Overall, more than 2500 fibres were scored per group. 
For sarcoglycan detection on muscle sections, a polyclonal antiserum raised against β-
sarcoglycan was used (dilution 1/1000; kindly provided by Dr. Carsten Bönnemann, 
Philadelphia; Bönnemann et al., 1996). 
ISOLATION OF IMMORTALISED MYOGENIC CELL LINES 
Two male homozygous H-2Kb-tsA58 (immorto) mice were obtained from Charles River 
(UK Limited, Margate, Kent, UK). These mice contain the thermolabile tsA58 mutant of 
the SV40 large T antigen under the control of the H-2Kb promoter. Isolated cells of this 
mouse strain are easily immortalised by growing them under permissive conditions: a 
temperature of 33 °C and the presence of  INF-γ (interferon-γ). To breed the SV40 large T 
gene onto the mdx background, advantage was taken from the fact that the dystrophin gene 
is localised on the X-Chromosome. The male immorto mice were bred with female mdx 
mice. F1 male offspring received one copy of the SV40 large T antigen gene and a Y-
Chromosome (that does not contain the dystrophin gene) from the immorto father and the 
mdx dystrophin point mutation on the X-chromosome from the mdx-mother. Therefore 
male F1 offspring are heterozygous for the SV40 large T gene and also dystrophin 
negative. Leg muscles from 6 week old  animals were then removed under sterile 
conditions under a flow hood. The muscles can then be kept for up to 5 days at 4°C in SolA 
(10 mM glucose, 30 mM HEPES, 130 mM NaCl, 3.0 mM KCl, and 0.003 mM phenol red 
(all from Sigma), 50 µg/ml gentamicin (Gibco BRL, Invitrogen, Karlsruhe, Germany)  pH 
7.6,) without loss of proliferative capacity of the muscle progenitor cells. Isolation of single 
myoblasts and satellite cells was based on a procedure previously described (Shoubridge et 
al., 1996).   
Muscle pieces (~150–300µg) were transferred into a tissue culture dish and washed 
repeatedly with SolA. They were then cut into smaller pieces (<1mm3) with two scalpels in 
a volume of 5 ml of SolA+Trypsin+EDTA (SolA + 0.05% (w/v) crystalline Trypsine 
(Gibco) + 0.02% (w/v) EDTA)  and transferred into a 15 ml Wheaton trypsinising flask 
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(Wagner und Munz, München, Germany) containing a magnetic stirrer bar. To completely 
transfer all muscle bits the tissue culture dish was rinsed twice with 5ml 
SolA+Typsin+EDTA, each time the remaining tissue fragments and the solution were 
transferred to the Wheaton flask.  
The muscle was now further disaggregated to isolate single cells by vigorous stirring for 15 
min on a magnetic stirrer. To keep the temperature at 37°C the Wheaton flask was kept in a 
heated water bath. The tissue debris was then allowed to settle on the ground for 1 min. The 
solution  containing the dissociated cells was decanted into a 50 ml centrifuge tube 
containing 15 ml of washing medium (Dulbecco’s modified Eagle Medium (DMEM,) + 
15% fetal calf serum (FCS,) + 50µg/ml gentamicin (all from Gibco)). Myoblasts that 
remain with the debris were isolated by stirring two more times for 15 min in 15 ml 
SolA+Trypsin+EDTA and decanting.  
The cells were then centrifuged down at ~ 500 for 10 min and the supernatant was 
discarded. The cells were now re-suspended in 2ml of Supplemented Growth Medium  
(SGM, PromoCell, Heidelberg, Germany).  
The goal of the next steps was to receive immortalised clones which originate from single 
cells. Therefore, the cell suspension was diluted 1/10, 1/50 or 1/100 in SGM+INF-γ 
(20U/ml Interferon-γ (murine, rekombinant) Life Technologies, Invitrogen, Karlsruhe, 
Germany). Then each dilution was plated in two 24 wells. Cells were incubated in a 
humidified incubator (5 % CO2) at 33°C. After two days the medium was changed to 
remove fragments of erythrocytes and disrupted myofibres.  After 4-5 days small colonies 
of dividing myoblast could be observed using a inverted phase contrast microscope. Single 
wells which originally received more than one cell could be identified because they contain 
more than one clone. After 1-2 weeks the cells were transferred to 6 wells and later to tissue 
culture dishes. After the first week SGM was replaced with DMEM + 15 % FCS + 
Glutamax1Supplement (Gibco). Clones that consist of small myofibre like single cells 
which show good division rates were then selected. Aliquots were frozen for later use and 
to save these lines. Myoblasts from these clones were then tested for the ability to fuse to 
myotubes. Fusion conditions were: a cell density of ~ 80%,  DMEM + 2% Horse Serum 
(Gibco) and  a temperature of 37°C. Two lines which divided and fused nicely were 
cultivated for over 1 year to ensure the immortalisation of these myogenic cell lines. If the 
cells grow to 90-100%  confluency they start to fuse spontaneously even in the presence of 
high serum concentrations. This can impair their ability to amplify and to fuse. Therefore, 
the cell lines were always splitted when they reached 70-80% confluency.            
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FORCE MEASUREMENTS ON ISOLATED MUSCLES 
The goal of a therapy of a muscular dystrophy is to re-establish normal muscle function in 
the affected patients. The best test to evaluate the effectiveness of a treatment in an animal 
model are therefore direct force measurements. One aim of this study was to develop and 
establish the necessary methodology for this kind of measurements in our laboratory. 
Suitable equipment was selected, purchased, interlinked and thoroughly tested before the 
experiments were started. Then force measurements on isolated mouse muscles were 
carried out basically as described (Petrof et al., 1993).  
 
Mice were first anesthetised with ketamine (130 mg/kg) and xylazine (20 mg/kg) to achieve 
a loss of deep pain reflexes. Entire muscles were then carefully removed from tendon to 
tendon. Animals were killed while still anesthetised. Isolated muscles were anchored on 
one end while the other end was connected to a force transducer (model Grass FT03; Astro-
Med, West Warwick, RI, U.S.A) coupled to a signal amplifier (model MIO 0500; FMI, 
Seeheim, Germany). During measurements the muscle was kept in a bath at 30°C in Ringer 
solution which was perfused with 95% O2 and 5% CO2. Muscle length and forced muscle 
lengthening were adjusted by a computer-controlled servomotor (model x.act LT 50; Linos, 
Göttingen, Germany). Electrical field stimulation was induced via platinum electrodes on 
both sides of the muscle (Fig. 2-1).  
 
Supramaximal stimuli with a monophasic pulse duration of 1 ms were delivered using a 
computer-controlled electrical stimulator (model ISG-8834/1-S; FMI, Seeheim, Germany). 
Signals were converted by an analog/digital converter (model Digidata 1200B; Axon 
Instruments, Union City, California, U.S.A.). Data recording and measurement protocol 
execution were handled by a custom-made software. After an initial adjustment time of 10 
min the optimal muscle length Lo (Lo is the length at which maximal twitch force is 
achieved) was determined and defined as the starting length. Measurements started 30 min 
after the muscle was removed. The following muscle parameters were evaluated: twitch 
force, tetanic force and resistance to eccentric contraction. 
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Fig. 2-1 Equipment for force measurement of isolated muscle. (adapted from World 
Precision Instruments, Berlin, Germany 1999)  
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Three twitch stimulations were recorded and the mean value was used to calculate maximal 
isometric twitch force. Maximal isometric tetanic force was then measured by stimulating 
the muscle at 125 Hz for 175ms, allowing a clear plateau in force to be attained. Specific 
force was calculated by normalising maximum tetanic force to total muscle cross-sectional 
area (CSA). CSA was determined by dividing muscle mass (milligram) by the product of 
fibre length (millimeter) and the average density of mammalian skeletal muscle taken as 
1.06 mg /mm3. 
 
Muscle of dystrophin-deficient mice (mdx) is especially susceptible to eccentric contraction 
which consists of forced muscle lengthening during maximal tetanic contraction. 
Successive eccentric contractions result in a more pronounced force drop in mdx muscle 
compared to wild type muscle. Measurements for eccentric contraction were carried out 
basically as described (Petrof et al., 1993). Briefly, the isolated muscle was stimulated at 
125 Hz for 700 ms; the muscle was held at Lo for the initial 200 ms and was then 
additionally stressed by lengthening (speed: 3 mm/s) of 10% Lo during the final 500 ms. A 
total of five contractions was recorded, each separated by a two min recovery period at Lo. 
The decline in maximal isometric force at Lo, obtained from the tetanic plateau reached 
during the first 200 ms of the first measurement of muscle stimulation, was compared to the 
value of the fifth measurement and used as an index of eccentric contraction induced 
muscle damage. 
GRIP STRENGTH OF LIVING ANIMALS 
Grip strength of living animals was determined as described previously (Connolly et al., 
2001) . In brief, mice were allowed to grasp a small metal trapeze which was attached to a 
force transducer (same as described above). The mice instinctively try to hold onto the 
trapeze. They were then pulled backwards until they released their grip (Fig. 2-2). The 
maximal grip strength was measured by a force transducer and recorded by a computer. 
The protocol for each mouse consisted of 10 repeated pulls separated by rest periods of 8 
sec. 
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The mean value of the three highest measurements was taken as the maximal grip strength. 
To evaluate if the animals showed different resistances to fatigue induced by repeated pulls 
we divided the mean of the three strongest pulls from measurements 1 - 5 by the mean of 
the three strongest pulls from measurements 6 - 10.  These values were then expressed as 
percentages. A value for resistance to fatigue of 100% indicates that the animals grip 
strength remained on the same level during the course of 10 pulls while a value of 0% 
indicates that the animal would not hold on any more during the last five measurements. 
 
 
 
Fig. 2-2 Grip strength measurement. After it has gripped the trapeze the mouse is gently 
pulled backwards until it releases its grip. Grip strength is measured by a force transducer and 
recorded by a computer. (after Connolly et al., 2001)  
STATISTICS 
Force measurement data were first statistically evaluated by an analysis of variance. The 
difference between two groups was further evaluated by the Tuckey test. Histological 
results (central nuclei, dystrophin and NADH counts) were compared between groups using 
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Students t test. Chi-square tests were used to test the hypothesis that adjacent dystrophin-
positive fibres decrease the probability of central nucleation in dystrophin-negative fibres. 
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PART III 
 
Muscle specific gene expression in MCK 1.35kb 
mini-dystrophin transgenic mdx mice 
 
 
INTRODUCTION  
Duchenne muscular dystrophy (DMD) is the most common primary muscle wasting disease 
in humans. Because of its high incidence, well characterised genetics, the complete lack of 
effective treatments and its severe progression with a fatal outcome, DMD has been 
considered a prime candidate for gene therapy (Hoffman and Dressman, 2001). Even 
though the concept of supplementing dystrophin-deficient muscle cells with a functional 
copy of the dystrophin gene is simple, its realisation has proven difficult (Somia and 
Verma, 2000).  Viral vectors capable of transferring therapeutic genes to a high number of 
cells in clinically relevant muscles such as the heart, diaphragm and limb muscles are under 
development. Ideally, several requirements should be met by the regulatory elements that 
drive expression of the therapeutic gene in the target tissue such as: 1) being strong enough 
to produce sufficient quantities of the therapeutic protein; 2) remaining active for the 
lifetime of the patient; 3) restricting expression to the target tissue; and 4) being small 
enough to fit into viral vectors with a limited packaging capacity (Walther and Stein, 1996; 
Cordier et al., 2001). It is noteworthy that strong constitutive viral promoters such as the 
CMV promoter are prone to cytokine-induced gene silencing and thus might not ensure 
long-term, stable expression (Harms and Splitter, 1995).  Moreover, viral promoters are 
active in many tissues other than skeletal muscle, which may also impair the safety, 
tolerability, and longevity of gene transfer (Ferrer et al., 2000; Pinto et al., 2000).  Indeed, 
the immune response against the vector and transgene product is aggravated when antigen-
presenting cells (APC) are infected by the vector and the transgene is expressed by APC 
(Hartigan-O’Connor et al., 2001; Yuasa et al., 2002). Therefore, regulatory elements, which 
are selectively active in the target tissue, but not in cells of the immune system, are 
increasingly recognised as being preferable for the purpose of somatic gene therapy 
(Weeratna et al., 2001). 
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The muscle creatine kinase (MCK) promoter is currently considered a good candidate to 
achieve the goal of muscle-specific gene expression in DMD. The MCK enzyme is 
abundantly expressed in skeletal muscle (Welle et al., 1999), and its regulatory regions 
have been well characterised in vitro, in transgenic animals and in gene transfer 
experimentation (Haecker et al., 1996; Deconinck et al., 1996; Yang et al., 1998; Hauser et 
al., 2000; Wang et al., 2000). The regulatory elements of the MCK promoter/enhancer are 
located within a 6.5kb sized region (Fig. 3-1). 
 
 
Fig. 3-1 MCK Promoter and MCK1.35dys construct. A) Depiction of the 6.5 kb full-length 
murine muscle creatine kinase regulatory region. Sites that contain major regulatory elements 
are indicated: the enhancers 1 and 2 (E1 and E2) and the proximal promoter region (PPR). 
Translation is initiated at the ATG codon. B) MCK1.35dys transgenic mice were produced by 
micro-injection of a 9.5 kb ClaI/SacII fragment, which contained a 1.35kb MCK promoter, a 
6.5kb mini-dystrophin, and a poly-A signal (pA).  
 
About half of this region is located upstream of the first exon within the 5’-untranslated 
region and the other half downstream of the first exon within intron1. Directly 5’ of the first 
exon lies a proximal promoter region (PPR) which has a size of approximately 385 bp. In 
promoter deletion studies the PPR was found to be indispensable for high level muscle 
specific gene expression. It contains at least one muscle specific regulatory element namely 
a MEF2 site. Two additional elements were identified that are important for optimal gene 
expression, they were called the MCK enhancer region 1 and 2 (E1 and E2). The E2 region 
lies in the first MCK intron 738bp downstream from the transcription initiation site 
(+738bp to +1598). It increases the activity of the basal promoter in skeletal muscle but not 
in the heart. The 206 bp E1 region (-1258bp to -1049bp) directs strong expression in 
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skeletal muscle and somewhat weaker expression in the heart (Johnson et al., 1989) 
Multiple transcriptional regulatory elements have been identified in this region: Two E-
boxes, MEF-2, AT-rich, and CArG sites, and Trex sites (Fabre-Suver and Hauschka, 1996; 
Hauser et al., 2000). An overview of the factors that bind to the different sites is given in 
Table 3-1. 
 
Table 3-1  Regulatory sites in the MCK Enhancer 1 (E1) 
 MCK E1 sites  DNA  binding factors  
 E-boxes   Members of MyoD family Lassar et al., 1989 
 MEF-2  MEF-2 Yu et al., 1992 
 AT-rich  MHox, MEF-2, Oct-1 Cserjesi et al., 1992 
 CArG  Serum response factor (SRF) Shore and Sharrocks, 1995 
 Trex  Trex-binding factor Fabre-Suver and Hauschka, 1996 
 
Virus mediated gene therapy requires packaging of the therapeutic construct consisting of 
the transgene and a promoter into the viral vector. However, the full-length MCK 
promoter/enhancer (6.5 kb) exceeds the limited packaging capacity of some of the most 
promising vectors for somatic gene therapy, such as adeno-associated virus and lentivirus 
based vectors (Scott et al., 2002). Therefore, several short versions of the MCK 
promoter/enhancer have been developed and tested in transgenic mice or gene transfer 
experimentation.  Unfortunately, most of these studies were limited by their short-term 
nature and/or were based upon analysis of reporter genes rather than therapeutic gene 
expression.  In addition, although previous studies have suggested unequal activity of MCK 
promoter/enhancer elements in slow-twitch and fast-twitch skeletal muscles, this issue has 
not been examined in detail.  
 
To address the aforementioned issues we created a transgenic mouse line which expresses a 
6.5kb mini-dystrophin under the control of a short muscle specific promoter. In the study 
mentioned above we have determined the efficacy of the short MCK 1.35 kb 
promoter/enhancer driving mini-dystrophin expression in multiple muscles for the entire 
lifetime of transgenic mice. Furthermore, we have evaluated whether there is any selectivity 
for expression within fast-twitch glycolytic fibres under these conditions.  Since large 
glycolytic muscle fibres are more prone to undergo necrosis in dystrophin-deficiency than 
31 
 
                                                                                                                     MCK Introduction 
small oxidative fibres (Karpati and Carpenter, 1986), sufficient transgene expression in this 
subset of fibres might be of particular clinical relevance.  
Our model provides important insights into the scenario that may be anticipated following 
systemic delivery of a viral vector containing MCK regulatory elements to drive therapeutic 
transgene expression in DMD. 
32 
 
                                                                                                                              MCK Results 
 
RESULTS 
Generation of dystrophin transgenic mdx mice 
We identified two founder animals that were positive for transgene sequences. Both 
founders were found to transmit the transgene to their offspring thus establishing two 
independent dystrophin transgenic lines. To ensure integrity of the promoter and 
promoter/dystrophin boundaries the complete MCK 1.35 kb promoter/enhancer region and 
adjacent parts of mini-dystrophin were sequenced for both lines. No mutations or 
rearrangements were found (data not shown). Both lines showed very similar expression 
patterns and expression levels for dystrophin once crossed onto the mdx background. If not 
otherwise stated the presented data are from transgenic line 2.  
Tissue-specific expression of dystrophin in transgenic mic 
In normal mice, expression of full-length dystrophin driven by endogenous promoters is 
limited to skeletal muscle, heart, and brain, and is very low or absent in other tissues. In 
contrast, muscles of mdx mice do not contain dystrophin except for a few so-called 
revertant fibres.  
Fig. 3-2. Immunoblot analysis of full-length (427 kDa) and mini-dystrophin (220 kDa) in 
various muscles and other tissues of wild-type (wt; C57BL/6) and transgenic (tg) mice. 
Muscle samples show a prominent band (myosin at 200 kDa) on the post transfer Coomassie 
gel (loading control). Dystrophin expression in transgenic mice is muscle-specific. It is strong 
in fast-twitch muscles but weak or absent in slow-twitch muscles, diaphragm and heart. 
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Western blot analysis of MCK1.35dys transgenic mice showed a muscle-specific, but 
more restricted pattern of dystrophin expression as compared to wild-type mice  
Expression was absent in non-muscle tissues, but varied considerably among different 
muscles. In detail, mini-dystrophin expression was 1) strongest in fast muscles such as M. 
tibialis anterior (TA), 2) intermediate in M. extensor digitorum longus (EDL) which is 
composed of fast-twitch and slow-twitch fibres and 3) absent or very weak in muscles 
containing mainly slow-twitch fibres such as M. soleus; and not detectable in the heart. This 
is in contrast to wild-type mice where expression levels of endogenous dystrophin are 
equally strong in all muscles and do not depend on muscle type (Fig. 3-2).. 
Muscle histochemistry and immunohistochemistry of transgenic mice 
Immunohistochemistry of transgenic mice revealed that even for dystrophin-positive 
muscles expression was not uniform and equal in all fibres, but a mosaic of dystrophin-
positive and dystrophin-negative fibres was observed. This pattern was seen in both 
transgenic lines, it was characteristic of a certain muscle (such as TA), and did not change 
in aged animals (Fig. 3-3). 
 
As dystrophin-positive fibres were larger than negative fibres we measured individual fibre 
cross sectional areas. This allowed us to compare the contribution of different fibres to the 
total muscle cross sectional area (CSA). In transgenic mice, 56% (TA) and 48% (EDL) of 
the CSA consisted of dystrophin-positive fibres (Table 3-2). Moreover, fibrosis in TA and 
EDL in 21-month-old dystrophin transgenic mice was slightly reduced if compared to non-
transgenic littermates (data not shown). In accordance with the immunoblot results, almost 
no dystrophin staining was observed in M. soleus and diaphragm of dystrophin transgenic 
mice. In these muscles, very few fibres were dystrophin-positive and their number did not 
exceed the number of revertant fibres in non-transgenic mdx mice of the same age. 
 
In addition, fibrosis of M. soleus and diaphragm in dystrophin transgenic mice were not 
reduced in comparison to non-transgenic littermates (data not shown). 
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Fig. 3-3 Immunofluorescent localisation of dystrophin in muscles from control and 
transgenic mice. TA (A, E, I, M, Q), EDL (B, F, J, N, R), M. soleus (C, G, K, O, S), and 
diaphragm (D, H, L, P, T). Panels (A-P) are from mice at the age of 7 months, panels (Q-T) 
from mice at the age of 20 months. Note the regularity of dystrophin expression in C57BL/6 
(A-D), its absence in mdx (E-H) and the mosaic pattern in adult muscle from both transgenic 
lines: line 2 (I-L) and line 1 (N-P) at the age of 7 months, and line 2 at the age of 20 months (Q-
T). Bar = 50 µm. 
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Table 3-2 Comparison of dystrophin expression, central nuclei and metabolic fibre type 
between transgenic and mdx mice 
        MCK1.35dys (tg)        mdx 
Dystrophin-positive fibres TA 56.3 ±   4.4 0.9 ± 0.7 
% of total area  EDL 48.2 ± 10.6 1.2 ± 0.7 
Fibres with central nuclei TA 33.2 ±   8.5 82.8 ± 2.8 
% of total area EDL 25.5 ±   3.5 86.7 ± 5.3 
Glycolytic fibres TA 64.6 ±   6.0 57.8 ± 8.0 
% of total area EDL 61.7 ±   7.2 53.2 ± 5.0 
 
TA and EDL from transgenic mice have a significantly higher percentage of dystrophin -
positive fibre area and less central nucleation as compared to mdx (P < 0.001). Transgenic EDL 
has a moderately increased percentage of glycolytic fibre area (P < 0.05). Mean ± standard 
deviation is shown. 
 
Each muscle has a characteristic composition of fibre types, which corresponds to the 
metabolic requirements of the muscle. A subset of fast-twitch muscle fibres depends mainly 
on glycolytic energy metabolism, whereas slow-twitch fibres depend on oxidation. The 
metabolic fibre type was visualised by the NADH reductase reaction, which is strong (dark) 
for oxidative fibres, and weak (light) for glycolytic fibres. In transgenic mice, a moderate 
increase in the number of glycolytic fibres was observed if compared to non-transgenic 
mdx mice (Table 3-2).  
 
To characterise the frequency, distribution and effect of MCK driven mini-dystrophin in 
TA and EDL muscles of transgenic mice (age 7 months), dystrophin expression, central 
nucleation and metabolic fibre type were assessed on the same sections (Fig 3-4).  
 
We observed a strong correlation between dystrophin expression and metabolic fibre type 
in transgenic mice: almost all dystrophin-positive fibres were large and glycolytic (98.5% 
for TA; 94.7% for EDL), whereas dystrophin-negative fibres were mostly small and 
oxidative (Table 3-3). 
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Fig. 3-4 Correlation of dystrophin expression, central nucleation and metabolic fibre type. 
Sections from 7-month-old C57BL/6 TA (A), mdx TA (B), transgenic TA (C), and transgenic 
EDL (D). Dystrophin immunostaining (red); nuclear bisbenzimide staining (blue); NADH-
tetrazolium reductase (glycolytic fibres light; oxidative fibres dark). In transgenic muscles, 
dystrophin-positive fibres are large; central nuclei are nearly absent (C, D). In contrast, 
dystrophin-negative fibres are smaller, mostly oxidative and often have central nuclei (C, D).  
Interestingly dystrophin expression depends on muscle fibre type. Dystrophin is nearly 
exclusively found in fast glycolytic fibres.  Also note the central nucleus in the revertant 
(dystrophin-positive) fibre in the mdx muscle (B). Bar = 50µm. 
A high rate of central nuclei is typically found in dystrophin-deficient muscle (mdx) and 
indicates ongoing cycles of necrosis and regeneration. Central nucleation increases with age 
and reaches 70-80 % in 3-6-month-old mdx mice. In transgenic TA and EDL, the area with 
centrally nucleated fibres was reduced by about 50 % if compared to mdx. This proportion 
remained stable even in aged mice (20 months). Muscles of transgenic mice that did not 
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express dystrophin, such as M. soleus showed similarly high levels of central nucleation as 
muscles of mdx mice. 
 
Table 3-3 Correlation between dystrophin expression, central nuclei and metabolic fibre 
type in transgenic mice. 
 
         MCK1.35dys (tg)  
% Dystrophin-positive fibres TA 5.6 ±   7.8
.with central nuclei EDL 2.7 ± 1.9
% Dystrophin-negative fibres TA 68.6 ± 10.3
.with central nuclei EDL 45.0 ± 20.6
% Dystrophin-positive fibres TA 98.5 ±   1.1
.which were glycolytic EDL 94.7 ± 6.7
% Dystrophin-negative fibres TA 78.4 ± 5.5
.which were oxidative EDL 69.5 ± 4.7
 
Fibres expressing dystrophin show a significant reduction of central nucleation. Note that 
almost all dystrophin expressing fibres are of the glycolytic fibre type. In contrast, dystrophin-
negative fibres are mostly oxidative. Mean ± standard deviation is shown. 
 
Dystrophin-positive fibres showed considerably less central nucleation as compared to 
dystrophin-negative fibres (Fig. 3-4). In dystrophin-positive fibres of transgenic mice, 
central nucleation was strongly reduced to 5.6 % in TA and 2.7% in EDL (Table 3-3). 
Therefore, mini-dystrophin expression appeared to be sufficiently protective against fibre 
degeneration. In dystrophin-negative fibres of transgenic mice, central nucleation was 
moderately reduced to 69% in TA and 45% in EDL when compared to corresponding mdx 
muscles. Interestingly, dystrophin-negative fibres with peripheral nuclei were frequently 
found directly adjacent to dystrophin-positive fibres. Central nucleation of dystrophin-
negative fibres not in contact with dystrophin-positive fibres was significantly higher than 
central nucleation of dystrophin-negative fibres surrounded by dystrophin-positive fibres 
(80.9 % versus 7.0 %; P < 10-6; Table 3-4). 
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Table 3-4 Neighbouring dystrophin-positive fibres reduce the rate of central nucleation in 
dystrophin-negative fibres of transgenic mice 
 
 number of fibres central nuclei (%) 
surrounded by dystrophin-positive fibres 57 7.0 
up to 75 % of total fibre surface area in contact with 
dystrophin-positive fibres 
255 18.4 
up to 50 % of total fibre surface area in contact with 
dystrophin-positive fibres 
443 36.1 
up to 25 % of total fibre surface area in contact with 
dystrophin-positive fibres 
529 61.2 
no contact with dystrophin-positive fibres 482 80.9 
 
Dystrophin-negative fibres of transgenic mice were scored for central nucleation according 
to their proximity with dystrophin-positive fibres. Contact with dystrophin-positive fibres 
led to a gradual reduction of central nucleation. Seven transgenic EDL muscles of 7-
months-old mice were scored. P < 10-6 for all groups if compared to the group of fibres 
with no contact with dystrophin-positive fibres. 
In contrast, revertant (dystrophin-positive) fibres of mdx muscles showed a high percentage 
of central nucleation (73%; TA; 7 months; n = 102) which indicates that revertant 
dystrophin is not fully protective. 
Force measurements on isolated muscles 
To compare the muscle function of transgenic, mdx and C57BL/6 mice in detail force 
measurements on isolated muscles are required. Three important parameters were 
measured: specific twitch force, specific tetanic force (Quinlan et al., 1992) and resistance 
to eccentric contraction. 
 
Twitch and tetanic contractions were measured under isometric conditions, i.e. the length of 
the muscle remained unchanged during contraction. A twitch is a short contractions in 
response to a single action potential that can be induced by a short (1 ms) electrical 
stimulation. Since the mechanical response lasts for about 100ms it is possible to induce a 
second action potential during the ongoing mechanical activity of the first stimulus. 
Therefore, when a muscle is stimulated by many rapidly successive electric pulses the level 
of tension increases until a maximum, tetanic force, as it is called, is reached (Fig. 3-5). 
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A protocol which emphasises the marked susceptibility of dystrophin deficient muscles to 
muscle damage consists of forced lengthening of the muscle during tetanic contractions. A 
series of these so-called eccentric contractions results in a dramatic force drop in mdx 
muscle, whereas normal muscle is more resistant to mechanical stress. In Fig. 3-5 data from 
tests of an EDL muscle are displayed, which demonstrated that the muscle force 
measurement worked as intended.  
 
Fig. 3-5 Measurement of muscle functions (Forces: red; electrical stimulation: blue)   
(A) single electric stimuli produce short “twitches” of the muscle. A rapid series of electric 
stimuli produces a tetanic contraction.  For an eccentric contraction the muscle is stretched 
when a tetanic contraction has reached its maximal force, which increases the strain on the 
muscle. (B) Comparison between transgenic and mdx muscle when subjected to a series of 
successive eccentric contractions. Note the great susceptibility of the mdx muscle and the 
resistance of the transgenic muscle. 
 
40 
 
                                                                                                                              MCK Results 
To monitor the long-term function of MCK-driven dystrophin expression force 
measurements were carried out in isolated muscles of transgenic mice at the ages of 3.5, 7, 
14, and 20 months and compared to non-transgenic littermates (mdx) and wild-type mice 
(C57BL/6). No difference in muscle function between dystrophin transgenic and mdx mice 
was found for muscles such as M. soleus and diaphragm that did not show significant 
dystrophin expression (data not shown). The EDL of transgenic mice showed a mosaic 
pattern of dystrophin expression (see above) and revealed an improved function if 
compared to EDL of age-matched, non-transgenic littermates (Fig. 3-6). Isometric force of 
transgenic mice was restored to wild-type levels. 
 
Fig. 3-6 Mechanics of isolated EDL muscle. Evaluation of specific twitch force (A), specific 
tetanic force (B), and resistance to eccentric contractions (C) for female wild-type (black), 
transgenic (grey) and mdx (white) mice. Between 5 and 18 muscles were analysed in every 
group. Data are presented as mean ± s.e.m. Statistically relevant differences between transgenic 
and mdx mice are indicated  (* P < 0.05; ** P < 0.01).  Differences between wild-type and mdx 
mice are highly significant for eccentric contraction (P < 0.001; not indicated). 
41 
 
                                                                                                                              MCK Results 
After twitch and tetanic force measurements the muscle were subjected to an eccentric 
contraction protocol. For all mouse lines tested the force drop remained fairly constant at all 
ages. Dystrophin transgenic EDL showed a significantly improved performance as 
compared to non-transgenic littermates (mdx; P < 0.01), but did not reach levels of wild-
type mice. The partial resistance to eccentric contractions in transgenic EDL corresponded 
well with the percentage of dystrophin-positive fibres. 
Grip strength of living animals 
Grip strength was measured to evaluate an overall beneficial effect of limited, transgenic 
mini-dystrophin expression at different ages. No significant difference between transgenic 
and non-transgenic (mdx) mice was detected at ages up to 14 months (data not shown). In 
contrast, wild-type mice were significantly stronger at all ages, and the difference in 
strength increased with age (data not shown). At 17 months of age, transgenic mice were 
significantly stronger than non-transgenic (mdx) mice (P < 0.05; Fig. 3-7). 
Fig. 3-7 Grip force measurements. 17-month-old female C57BL/6 (black), transgenic 
(grey) and mdx (white) mice. Between 8 and 10 mice were tested in every group. Data are 
presented as mean ± s.e.m. Statistically relevant differences between transgenic and mdx mice 
are indicated (* P < 0.05). 
 
  
42 
 
                                                                                                                              MCK Results 
Moreover, we measured the resistance to fatigue against repeated grip strength pulls. There 
was no difference between mdx and transgenic mice, but they both were significantly less 
resistant to fatigue than wt mice (Fig. 3-8). While wt mice could maintain a constant force 
over 10 repeated pulls, the force dropped strongly for the other two models. After the 
measurement, wt mice immediately started to move in the cage. In contrast, mdx and 
transgenic mice made no attempts to move around and also had a much higher breathing 
frequency.  
 
 Fig. 3-8 Resistance to fatigue. Female C57BL/6 (black), transgenic (grey) and mdx (white) 
mice aged between 3-17 months .  8 - 10 mice were tested in every group.  Data are presented 
as mean ± s.e.m. Differences were not significant between mdx and transgenic mice. But both 
were significantly different when compared to C57BL/6 mice at all ages (** P < 0.001; * P < 
0.05).  
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DISCUSSION 
In this study we demonstrate that transgenic expression of mini-dystrophin driven by a 1.35 
kb muscle creatine kinase (MCK) promoter partially protects skeletal muscle throughout 
the lifetime of dystrophin-deficient (mdx) mice. Interestingly, we observed a preference of 
transgenic dystrophin expression for glycolytic fibres in fast skeletal muscle of two 
independent mouse lines.  Our detailed histological and functional analysis of several 
muscles provides new insights into the therapeutic effects of mosaic transgene expression.  
 
Ideally, somatic gene therapy of muscular dystrophy will result in adequate transgene 
expression in every muscle and in every muscle fibre of the body. However, current gene 
delivery protocols suffer from several limitations: skeletal muscle is distributed throughout 
the body and accounts for more than 40% of total body mass, many muscles such as heart 
and diaphragm are difficult to reach directly, and systemic vector delivery implies 
additional risks such as increased toxicity and immunogenicity (Kay et al., 2001). 
Therefore, gene delivery is likely to be incomplete and to result in unequal or mosaic 
transgene expression for different muscles or muscle fibres. So far, few attempts have been 
made to determine the level and distribution of transgene expression that would permit 
functional improvement. Phelps et al. compared several lines of transgenic mdx mice with 
varying levels of dystrophin expression and fibre-by-fibre mosaics. They concluded that 
uniform dystrophin expression at a level of 20-30% in all fibres efficiently corrects the 
dystrophic phenotype. In contrast, high expression levels restricted to a smaller number of 
fibres were not equally protective (Phelps et al., 1995). Interestingly, no negative effect was 
observed in transgenic mice that strongly overexpress dystrophin in all tissues by an 
ubiquitously active viral promoter (Cox et al., 1993). 
 
Most studies use central nucleation as an endpoint in gene transfer and transgenic 
experimentation and correlate the overall levels of central nucleation and dystrophin 
expression in entire muscles. Our approach to score large numbers of individual fibres in 
different muscles allowed for additional conclusions: central nucleation in transgene 
expressing fibres is reduced to almost wild-type levels (5.6 % for TA and 2.7 % for EDL). 
Therefore, the 6.3 kb mini-dystrophin may be fairly protective even if it is not strongly 
overexpressed. This is in accordance with the original observation of this mini-dystrophin 
in a very mildly affected patient  (England et al., 1990). However, precise phasing of the 
dystrophin rod deletion may lead to functionally improved mini-dystrophin molecule 
44 
 
                                                                                                                        MCK Discussion 
(Harper et al., 2002). In contrast, dystrophin-positive, so-called revertant fibres of non-
transgenic mdx mice showed high levels of central nucleation close to levels in dystrophin-
negative fibres. Revertant dystrophins are thought to arise from somatic deletions or post-
transcriptional exon skipping that excise the mdx stop codon (Uchino et al., 1995; Wilton et 
al., 1997; Lu et al., 2000; Crawford et al., 2001). Our findings may indicate that the 
majority of naturally occurring revertant dystrophin is dysfunctional.  
 
Interestingly, even dystrophin-negative fibres in muscles with mosaic transgene expression 
show a moderately reduced rate of central nucleation if compared to non-transgenic 
littermates (69% in transgenic TA compared to 82% in mdx TA; 45% in transgenic EDL 
compared to 86% in mdx EDL). We cannot rule out that "dystrophin- negative" fibres 
express low amounts of dystrophin that are below the detection threshold of our 
immunohistochemical analysis. However, it appears unlikely that such very low transgene 
levels would protect muscle fibres from degeneration. Moreover, we observed lower levels 
of central nucleation mostly in dystrophin-negative fibres that were in close vicinity to 
dystrophin-positive fibres. Therefore, we hypothesise that dystrophin-negative fibres may 
benefit from a positive bystander effect. Under these conditions, dystrophin-positive fibres 
may carry the main mechanical burden, thereby leading to reduced stress and cell death of 
the adjacent, more vulnerable dystrophin-negative fibres. Moreover, fibre necrosis in 
dystrophic muscle is accompanied by inflammation which results in further deterioration of 
the muscle (Porter et al., 2002; Spencer et al., 2001). Therefore, an overall reduction of 
inflammation may contribute to a further prolonged survival of all muscle fibres.  
 
The reduction of central nucleation is a well-accepted histological outcome measure of 
therapeutic or transgenic intervention in muscular dystrophies. However, the primary and 
most clinically relevant goal is the improvement of force generation. The mdx mouse has 
been criticised as an animal model for human dystrophin-deficiency since caged mdx mice 
do not reveal severe functional impairment on first sight. Maximum tetanic force is not 
compromised in several hindlimb muscles of mdx mice. This is because a decrease in 
maximum tetanic force per muscle cross sectional area (specific force) is compensated by a 
gain in muscle mass and diameter (Coulton et al., 1988; DelloRusso et al., 2001). However, 
specific forces and resistance to eccentric contractions are clearly impaired in mdx muscle 
if compared to controls. These deficits are due to the lack of dystrophin and worsen with 
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age. To further evaluate the effect of transgenic mini-dystrophin expression we ascertained 
functional parameters in isolated EDL muscles of young adult and aged mice. 
For specific twitch and tetanic forces as well as the resistance to eccentric contractions, we 
found significant improvements in transgenic mice as compared to their non-transgenic 
littermates. This improvement was most pronounced in aged mice, which is in agreement 
with previous results (DelloRusso et al., 2001; Lynch et al., 2001). Resistance to eccentric 
contractions was the most sensitive parameter, showing significant differences for the EDL 
muscle in all age groups (Moens et al., 1993).  
 
It is an interesting question why skeletal muscles of mdx mice are highly susceptible to 
eccentric contraction while other mechanical functions are not substantially affected. 
Two additional observations in mdx mice support this notion: The diaphragm is most 
severely affected, and intensive downhill running results in increased membrane leakage. 
Both are naturally occurring models for eccentric contractions, i.e. muscle lengthening 
during contractile work. Apparently, mdx muscle can sustain stress connected with normal 
muscle contractions, but cannot cope with the additional physical stress during eccentric 
contractions.  
  
Grip force measurements are non-invasive tests, which allow for longitudinal studies 
without killing the mice. However, grip force appeared to be a less sensitive parameter if 
compared to isolated muscle measurements, since a significant difference between 
transgenic mice and non-transgenic littermates was only detected in aged mice. Similarly, 
the degree of muscle fibrosis was only reduced in EDL and TA of aged transgenic mice as 
compared to their non-transgenic littermates.  
In other studies mdx mice had to complete exercise protocols such as swimming or running 
(Hayes and Williams, 1998; Granchelli et al., 2000; Vilquin et al., 1998). It was noted that 
mdx mice show earlier and stronger signs of exhaustion than normal controls. Apparently, 
dystrophin-deficiency in mice results in a phenotype that allows for normal movement and 
behaviour of caged animals, but additional exercise reveals physical limitations. To 
quantify increased fatigue we measured grip strength of 10 successive pulls (see above). 
Interestingly a highly significant fatigue in mdx mice was detected when compared to wt 
mice. This protocol is a fast, non-invasive, repeatable and sensitive method to evaluate the 
overall physical performance of mdx mice. Importantly, this method allowed a sensitive 
characterisation of the mdx phenotype already at 3 months of age. However, this method 
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does not allow to distinguish among a number of possible causes for increased fatigue such 
as limb muscle weakness, heart insufficiency, influence on behaviour, or breathing 
insufficiency. However the increased breathing rate that we observed in the transgenic 
animals and mdx mice after repeated grip strength measurements may be caused by the 
very pronounced phenotype that is found in the diaphragm of these mice. Stedman et al. 
have argued that the eccentric mode of action and a high respiratory work load in rodents 
are the reasons why the mdx diaphragm is more severely affected than other muscles 
(Stedman et al., 1991). When the resistance to fatigue of MCK1.35dys mice was measured, 
no improvement was detected in comparison to mdx mice. Since dystrophin was not 
expressed in heart and diaphragm of the transgenic mice, an impairment in cardio-
respiratory function may have been responsible for the increased overall fatigue. 
 
Another finding of interest in our study was a mosaic pattern of transgene expression in 
several muscles within two independent transgenic mouse lines, which suggests that this 
pattern is not due to a position effect of a specific integration site in the mouse genome, but 
rather an intrinsic property of the MCK promoter. We hypothesise that the MCK promoter 
shows higher activity in fast-twitch muscles and glycolytic fibres as compared to slow-
twitch muscles and oxidative fibres. Evidence from several studies of the function and 
distribution of muscle creatine kinase, from MCK promoter analysis and from in vivo 
expression studies support this notion. Indeed, muscle type creatine kinase is mainly 
located at sites of high ATP consumption and participates in the regeneration of ATP from 
phosphocreatine (Bessman and Carpenter, 1985; Wallimann et al., 1992). Therefore, 
muscle creatine kinase plays a pivotal role in fibres that depend on glycolysis for energy 
generation. Accordingly, fast-twitch glycolytic muscles contain higher levels of MCK-
mRNA and MCK-activity in comparison to slow-twitch oxidative muscles (Andres et al., 
1990; Yamashita and Yoshioka, 1991; Tsika et al., 1995). 
 
Regulatory elements of the MCK promoter/enhancer that are responsible for muscle-
specific expression and for differential expression in fast-twitch, slow-twitch and cardiac 
muscles have been identified (Johnson et al., 1989; Shield et al., 1996). MCK1.35 used in 
this study contains two major regulatory elements: a muscle-specific enhancer (E1) located 
1.1 kb upstream of the transcription start site and the proximal promoter region. The 
intronic enhancer (E2) is not included.  MCK promoter/enhancer constructs have been used 
in several studies to achieve muscle-specific gene expression in transgenic animals, and 
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include variants of 6.5kb, 3.3kb and 570bp (Johnson et al., 1989; Hauser et al., 2000). Most 
of these studies focused on transgene expression in fast-twitch skeletal muscles and 
reported strong variations in MCK-driven expression: 1) between different transgenic lines; 
and/or 2) between different muscles; and/or 3) a mosaic pattern of expression in muscles 
(Lee et al., 1993). Although strong transgene expression has been demonstrated in 
diaphragm in some exceptions (Cox et al., 1993; Squire et al., 2002), expression levels are 
usually highest in fast-twitch skeletal muscles and considerably lower in slow-twitch 
skeletal muscle, diaphragm and heart  (Phelps et al., 1995; Harper et al., 2002; Johnson et 
al., 1989; Shield et al., 1996; Wells et al., 1995; Donoviel et al., 1996; Corrado et al., 1996; 
Ahmad et al., 2000). 
 
As with our study, most in vivo studies on MCK promoter/enhancer function are based 
upon observations in transgenic animals. While it appears theoretically possible that a 
different expression pattern could result after viral gene transfer (particularly when the 
transgene does not stably integrate in the host genome), it is noteworthy that MCK-driven 
transgene expression remained muscle-specific after adenoviral gene transfer (Larochelle et 
al., 2002; Scott et al., 2002). Previous gene transfer studies have mainly examined fast-
twitch muscles or failed to directly compare expression in fast-twitch and slow-twitch 
muscles. However, MCK-driven luciferase expression was high in fast-twitch muscle and 
poor in heart if normalised to activity of the RSV promoter (42% for skeletal muscle and 
0.7% for heart) (Larochelle et al., 1997). 
 
This comprehensive study allows for the first time a direct correlation between dystrophin 
expression, metabolic fibre type and central nucleation in transgenic mice using a MCK 
promoter/enhancer construct.  In conclusion the MCK promoter/enhancer provides not only 
muscle-specific expression, but also different levels of expression depending on the 
metabolic characteristics of the muscle and its component muscle fibres. The MCK 
promoter seems to be highly appropriate in applications in which transgene expression 
should be restricted to skeletal muscle and high expression in a limited number of muscle 
fibres is sufficient. This may include DNA immunisation (Gebhard et al., 2000), metabolic 
engineering for systemic delivery of non-muscle proteins (Bou-Gharios et al., 1999) and 
experiments in which expression of a transgene - specifically in glycolytic fibres - is 
desirable (Lin et al., 2002). Since large, glycolytic fibres are especially vulnerable to the 
dystrophic process in DMD, high levels of transgene expression in these fibres is likely to 
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be essential (Karpati and Carpenter, 1986). However, therapeutic efficacy of the MCK 
promoter might still be limited in gene therapy of muscular dystrophies, since a more 
widespread and even expression of the transgene is probably needed. On the other hand, it 
may be possible to overcome these limitations by modifying the MCK promoter/enhancer 
or by coupling MCK with regulatory elements from other muscle-specific or ubiquitous 
promoters. As for now, in vivo expression analysis of such constructs has focused solely on 
fast-twitch skeletal muscle (Hauser et al., 2000; DelloRusso et al., 2002). Further studies in 
a larger variety of muscles of dystrophic animals will be required to fully ascertain the 
therapeutic efficacy and fibre type specificity of such constructs in the context of muscular 
dystrophies. 
 
These experiments discussed above focussed on tissue specific gene expression achieved 
through the use of a tissue specific promoter in a transgenic mouse model. In a therapeutic 
gene therapy approach the tissue specificity may not only be determined through the control 
of gene expression, but also through the specificity of the applied gene transfer system for 
the target tissue. To accomplish optimal tissue specificity it may be therefore beneficial to 
combine a tissue specific promoter with a tissue specific method of gene delivery. The high 
synergy of such an approach was demonstrated in a system for lung specific gene 
expression after adenoviral gene transfer. By combining transductional targeting to a 
pulmonary endothelial marker and transcriptional targeting the selectivity of transgene 
expression for the lung was largely improved (Reynolds et al., 2001). For the DMD therapy 
a muscle specific promoter should be combined with a delivery method that targets all 
affected muscle tissues.  
 
Direct injections into the muscle would allow some level of specificity. Unfortunately, 
transgene expression is restricted to the injection site and the near vicinity (O’Hara et al., 
2001). For human muscular dystrophies this approach would require hundreds of 
intramuscular injections. Recently, improved uptake of naked DNA, lipid coupled DNA 
and viral vectors into muscle was reported by electrotransfer (Cappelletti et al., 2003), 
ultrasound (Danialou et al., 2002), and the modulation of Starling forces (Cho et al., 2000). 
To reach all muscles including the heart and the diaphragm, systemic delivery through 
intravascular routes would be favourable. For systemic delivery, several obstacles need to 
be overcome: capillaries may transport the therapeutic agent to many non-muscle tissues, 
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and the therapeutic agent has to pass the blood vessel walls and to enter the muscle cells 
with high efficiency. 
 
Use of Ads for gene therapy of adult skeletal muscle is restricted by low levels of the 
primary virus attachment receptor, the Coxsackie- and adenovirus receptor (CAR), on the 
surface of mature myofibres (Bergelson et al., 1998; Nalbantoglu et al., 1999). Especially 
after systemic injection the majority of Ad is not found in muscle but in other tissues that 
express higher levels of CAR, most notably hepatocytes. Retargeting of Ad therefore 
depends on a twofold strategy (Thirion et al., 2002). First, the ablation of the national 
tropism by removing the CAR binding site and other sites which still have to be identified 
that allow interactions with non-muscle cells (Alemany and Curiel, 2001); and second, the 
introduction of binding moieties that allow to specifically target muscle fibres (Fig. 3-9).  
 
Fig. 3-9 Strategy for adenovirus targeting and enhanced gene delivery into the targeted 
tissues. (I) In wild-type adult skeletal muscle Ad gene-transfer is limited by the low amount of 
CAR on myofibres. This low tropism could be overcome by: (II) an increase of CAR 
expression on the target tissue surface, (III) direct targeting through genetic engineering, e.g. 
insertion of targeting ligand into the Ad fibre, fibre-swab between Ad-serotypes, or 
modifications of the penton or hexon sub-units of the viral capsid, (IV) coupling of targeting 
compounds such as antibody- or bispecific protein-adapters. 
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Recently, we have demonstrated that antibody-mediated targeting of Ad resulted in muscle 
specific targeting. A synthetic 33-amino-acid immunoglobulin G (IgG) binding domain 
derived from staphylococcus protein A was inserted into the Ad fibre (Volpers et al., 2003). 
The modified fibre bound IgG with high affinity and retained the ability to assemble as 
fibre-trimers to the viral capsid. Preincubation with monoclonal antibodies against muscle 
surface molecules like neuronal cell adhesion molecule (NCAM) or α7-integrin resulted in 
an up to 77-fold increase in reporter gene transfer in differentiated primary human 
myoblasts. 
This IgG-binding Ad vector holds promise to allow a) easy systematic screenings for the 
identification of new tissue specific surface receptors, b) targeted gene transfer to a wide 
variety of cell types without laborious specific modifications of the capsid for each 
individual target through the use of different antibodies, and c) a double targeting strategy 
for skeletal muscle through the combination of a muscle specific gene control element with 
targeted gene transfer.  
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PART IV 
 
Gentamicin Induced Read-Through of Stop Codons 
 
 
INTRODUCTION 
For decades aminoglycoside (AG) antibiotics have been used to fight bacterial infections. 
The structural and biochemical properties of AG explain both the therapeutic and side-
effects of these drugs. AG interact with ribosomal RNA's (rRNA) inducing errors of the 
cellular translation machinery .They bind to a highly conserved decoding region of rRNA. 
The structure of the RNA complexed to gentamicin was recently resolved (Yoshizawa et 
al., 1998). The affected RNA region normally mediates the precise codon-anticodon 
pairing. When aminoglycosides are bound to this region the rRNA conformation is 
modified and the accuracy of the translation process is reduced. Although this interaction 
with rRNA takes place in various organisms, bacterial translation appears to be more 
sensitive to AG than mammalian translation (Lynch and Puglisi, 2001). Furthermore, 
mitochondrially encoded rRNA may be more vulnerable to AG than nuclear encoded 
rRNA, which may explain some of the side-effects, i.e. ototoxicity and nephrotoxicity 
(Guan et al., 2000).  
 
Several in vitro experiments indicated that AG-related interference with translation may be 
used for therapy of inherited disorders. A certain proportion of these disorders is caused by 
nonsense mutations, i.e. a single nucleotide exchange replacing a codon for an amino acid 
by a stop codon resulting in premature termination of the respective amino acid chain. The 
resulting truncated proteins are normally not functional and are rapidly degraded. 
  
Several independent groups have shown in cellular models of cystic fibrosis, Hurler's 
disease and DMD, that AG are capable of inducing “read-through” of such nonsense 
mutations generating full-length protein that is otherwise deficient (Howard et al., 1996; 
Howard et al., 2000; Keeling et al., 2001). These full–length proteins may carry an amino 
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acid substitution as a consequence of the incorporation of an amino acid at the site of the 
stop codon but in most cases will be nevertheless functional (Fig. 4-1). 
 
 
Fig. 4-1 Gentamicin induced “read-through”. The wt mRNA encodes the full-length 
dystrophin protein. At the ribosome a glutamine-carying tRNA normally binds to the 
corresponding CAA sense codon. In the mdx mouse mRNA a single base transition (CAA > 
UAA) codes for a premature stop codon which is recognised by release factor proteins (RF). 
The RFs bind to the mRNA and terminate the translation. Gentamicin binds close to the 
ribosomal tRNA recognition site and interferes with correct codon recognition. Now, not only 
RFs bind to the mRNA but occasionally also a tRNA carrying an amino acid. Therefore, full-
length dystrophin can be assembled carrying an amino acid substitution if another amino acid 
than glutamine is incorporated. (Adapted from Mankin and Liebman, 1999)  
 
 However, the amount of protein generated was dependant on several factors such as the 
dosage and composition of the AG as well as the exact sequence of the mutation, and even 
in the best case scenario it did not reach the levels of wild type cells. Moreover, in vivo 
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application of subtoxic doses of AG has resulted in little if any functional benefit (Clancy et 
al., 2001). 
 
Therefore, the findings of Barton-Davis et al. reporting that AG can restore functional 
dystrophin and associated proteins in mdx mice came as a welcome surprise for the 
scientific community and the lay public (Barton-Davis et al., 1999; Mankin and Liebman, 
1999). A number of arguments in favour of AG therapy led to the rapid initiation of several 
clinical trials for DMD: 1. DMD is a fatal disorder for which other therapies are not really 
effective. 2. Molecular therapeutic approaches such as gene or stem cell therapy may be 
years ahead and/or may not live up to the expectations. 3. Gentamicin can be systemically 
administered and thereby potentially reach all affected muscles. 4. It can be easily produced 
in sufficient quantities 5. It is a widely used AG, an approved, conventional drug with a 
long-standing record in safety and tolerance. While a restoration of dystrophin to normal 
levels was not anticipated, even levels as low as 20% of the normal level may prevent 
muscle fibre necrosis and improve muscle function (Ahmad et al., 2000; Yang et al., 1998). 
The majority of mutations of the dystrophin gene, such as large deletions, are unlikely to be 
beneficially influenced by gentamicin treatment. However, it was estimated that 5- 15% of 
all DMD cases are due to nonsense mutations of the dystrophin gene, and such cases would 
be candidates for gentamicin therapy (Mendell et al., 2001). 
 
Up to the present time, results of three clinical trials using gentamicin in DMD/BMD 
patients carrying nonsense mutations of the dystrophin gene have been reported; two in 
abstract form and one as a full communication (Dubowitz, 2002, Serrano et al., 2001, 
Wagner et al., 2001). The fully reported trial by Wagner et al. did not reveal an increase of 
dystrophin expression in four gentamicin-treated DMD/BMD patients (Wagner et al., 
2001), neither did the trial by Serrano et al. in twelve patients. By contrast, G. Nigro in a 
special workshop reported an immunohistochemical increase of dystrophin expression for 
one out of four gentamicin-treated DMD patients, but immunoblotting data were not 
presented (Dubowitz, 2002). The latter trial consisted of 3 cycles of daily gentamicin 
infusions for one week each, while in the first two trials, a 14-day protocol of daily 
infusions, very similar to the mouse study (Barton-Davis et al., 1999), was applied. 
Interestingly, a decrease in creatine kinase (CK) levels during gentamicin treatment was 
noted in several patients although an increase in dystrophin expression was not detected. 
The clinical significance of this finding is unclear at the moment. In summary, in contrast 
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to the reported mouse data (Barton-Davis et al., 1999), clinical trials in DMD patients with 
short courses of subtoxic gentamicin infusions did not result in clinical benefit. Therefore, 
independent experimentation in the mdx mouse was carried out to evaluate the effect of 
gentamicin treatment. 
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RESULTS 
Because a treatment for DMD is in urgent need,  treatment of mdx mice with gentamicin 
was simultaneously tested in two laboratories. The author conducted  the work in the 
laboratory of Hanns Lochmüller which is described here in detail. Supporting data from the 
trial in Montreal are marked as such.  
In the Montreal-study (Laboratory of George Karpati, Neuromuscular Research Group, 
Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada), 
gentamicin was applied as described in reference 2 (data not shown). Groups of 6 mdx mice 
were used. Starting at age 4-6 days mice were injected subcutaneously with gentamicin 
sulfate (34mg/kg or 17 mg/kg; Sigma) or normal saline daily for 14 days.  
In the Munich-study effects of gentamicin on dystrophin expression were tested in vitro and 
in vivo.  
Establishment of immortalised dystrophin negative cells 
For in vitro experiments, myogenic cells were needed that are dystrophin deficient due to a 
nonsense mutation of the dystrophin gene (mdx cells). However, cultures of primary 
murine myoblasts are very heterogeneous, and the cells cannot be propagated for an 
extended time in tissue culture. Therefore, we generated immortalised lines of dystrophin 
deficient myogenic (mdx) cells. We used the H-2Kb-tsA58 mouse system which allows 
quick isolation of immortalised cells from different tissues. Cell lines were isolated from 
normal and mdx mice that were cross-breeded with “immorto” mice. The resulting cell 
lines divide indefinitely when cultivated at 33°C and in the presence of INF-γ. They have 
the additional advantage that the immortalising SV40 large T antigen can be shut down 
when the cells are cultivated at 37°C and INF-γ is withdrawn. Clones from single muscle 
progenitor cells of mdx × H-2Kb-tsA58 mice were isolated and characterised. Several 
clones had the appearance of myoblasts when grown at low densities. Under fusion 
conditions the cells fused to form elongated multinucleated myotubes (Fig. 4-2).  
 
Fusion started after 36 hours and the majority of cells fused after 3-5 days. Importantly, 
most myotubes displayed spontaneous contractions after 5-7 days which is a very good 
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Fig. 4-2  Immortalised dystrophin negative cells. (A) At low densities the myoblasts divided 
rapidly. (B) At higher densities and fusion-conditions the cells fused to multinucleated 
myotubes which contracted spontaneously. Arrows in the magnified window indicate the 
position of single nuclei.  
 
indicator that cells had the potential of differentiated muscle cells. Because human 
myoblasts whose life span were prolonged by the expression of viral tumor genes 
(Lochmüller et al., 1999) and primary murine myoblasts show signs of senescence after 
multiple cell divisions we wanted to assess that our clones were truly immortalised. Two 
independent clones were continuously cultivated for more than 12 months. The speed and 
the total number of cell divisions were measured based on cell counts and splitting rates. 
Overall, cells divided approximately every 22 hours. More than 400 cell divisions were 
monitored. To ensure that the cultures kept their myogenic features they were regularly 
tested for fusion and contraction competence. The cells also withstood repeated freezing 
and thawing without losing any of their characteristic features, which allows convenient 
storage and distribution of these cell lines. As a control, we isolated an immortalised cell 
line from a dystrophin positive wild-type mouse with the same method. Western blot 
analysis revealed that dystrophin was expressed in fused and unfused cells from the 
immortalised control cell line but was absent in cultured mdx cells (data not shown). 
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In vitro gentamicin treatment  
Dystrophin negative cells were treated with different concentrations (200-500µg/ml) of 
gentamicin sulfate from two different suppliers. Treatment was continued for 14 days to 
ensure that dystrophin could accumulate to detectable levels.  Cells were either cultivated 
under normal growing conditions or under fusion conditions. High concentrations of 
gentamicin sulfate resulted in lower fusion rates and deattachment of the cells (Table 4-1). 
Therefore, it seems that too high levels of gentamicin interfere with the eukaryotic 
translation machinery and thereby block proliferation and differentiation. 
 
Table 4-1 in vitro effect of gentamicin treatment on cultivated mdx cells (fusion conditions) 
Immortalised Cell line Control mdx mdx mdx mdx mdx 
Gentamicin (µg/ml) / / 200 300 400 500 
Fusion to myotubes +++ +++ +++ ++ ++ + 
Presence of deattached cells - - - + ++ ++ 
Dystrophin staining +++ - - - - - 
 
A dystrophin signal could not be detected either in directly stained myotubes (data not 
shown) nor in western blot analysis of cell lysates (Fig. 4-3). 
In vivo gentamicin treatment 
For in vivo experiments, groups of 4 mdx mice were used. Mice were 5 weeks old at the 
beginning and 12 weeks old at the end of the experiment. Three courses of daily 
intraperitoneal gentamicin sulfate injections were given for one week (8.5 mg/kg for female 
and 34mg/kg for male mdx mice). Gentamicin sulfate was purchased from GibcoBRL 
(Batch 3034117; composition according to the supplier: C1 - 28%; C1a - 20%; C2a and C2 
- 52%). The 3 courses were separated by 2-week intervals. On the day following the last 
injection, the resistance to eccentric muscle contractions was measured (Yang et al., 1998) 
and muscles were collected for immunohistochemistry and immunoblotting. No fatality 
was noted during the treatment and no obvious side-effects were observed.  
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Fig. 4-3 Dystrophin expression in immortalised mdx myotubes that were treated in vivo 
with different concentrations of gentamicin (200-500µg / ml).  Two exposures of the 
dystrophin immunoblot and the corresponding post-transfer Coomassie blue stained gel are 
shown.  Lane 1, protein lysate of tibialis anterior muscles from a dystrophin positive wt mouse 
and lane 2, lysate of immortalised cells of a wt mouse -  as positive controls. Note that no 
dystrophin was detected in the cell lysates of gentamicin-treated immortalised mdx cells even 
when the blot was overexposed. 
Muscle function measurements 
Resistance to eccentric muscle contraction was measured for EDL muscles (M. extensor 
digitorum longus) according to standard protocols (Yang et al., 1998). Gentamicin-treated 
mdx mice were not different compared to untreated control mdx mice in contrast to the very 
good resistance of age matched C57BL/6 muscles (Table 4-2).  
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Table 4-2 Resistance to eccentric muscle contraction was measured for EDL muscles. 
male mice female mice  
force drop SD force drop SD 
C57BL/6 (control) 20.1 % 4.1 % 14.2 % 3.8 % 
mdx (untreated) 68.1 % 9.7 % 65.0 % 12.2 % 
mdx (gentamicin-treated) 67.9 % 12.7 % 61.6 % 8.9 % 
 
The maximum force at the first tetanic contraction is compared to the maximum force at the 
first eccentric contraction. The force drop is given as a percentage +/- standard deviation. A 
high force drop is observed in muscles with decreased membrane stability such as dystrophin 
deficient muscle. Gentamicin-treated mdx mice were not different compared to untreated 
control mdx muscles in contrast to the very good resistance of age matched C57BL/6 muscles. 
Fig. 4-4  Immunohistochemistry for dystrophin and β-sarcoglycan. Representative 
results (M. tibialis anterior) of dystrophin-positive control mice (C57BL/6), of gentamicin-
treated mdx mice and of untreated mdx mice are shown. Revertant fibres are indicated by 
an asterisk. In muscles of gentamicin-treated mdx mice an increase of dystrophin or 
sarcoglycan was not detected. 
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Detection of dystrophin expression 
Sections of various skeletal muscles (M. tibialis anterior, M. soleus, M. quadriceps femoris, 
M. extensor digitorum longus, diaphragm) were analysed immunohistochemically for the 
expression of dystrophin and sarcoglycans. Muscle sections of mdx and C57BL/6 mice 
were used as controls. An increase of dystrophin or sarcoglycans in muscles of gentamicin-
treated mice was not observed (Fig. 4-4). 
 
Western blot analysis of dystrophin does not give information about the localisation and 
distribution of the protein of interest, but is very sensitive and also allows an estimate of the 
size of the detected protein. In the case of a gentamicin induced read-through mechanism 
full-length dystrophin (427kDa) would be expected.  Muscle protein lysates of M. tibialis 
anterior and heart from gentamicin-treated mdx mice were analysed for dystrophin 
expression on western blots. Lower amounts  (50% and 17%) of muscle protein from 
dystrophin-positive C57BL/6 mice were used as positive controls, and blots were 
overexposed. We estimated that our method could detect dystrophin levels as low as 3 % of 
the normal. However, no specific signal for dystrophin was present in gentamicin-treated 
mdx mice (Fig. 4-5). 
 
 In conclusion, gentamicin treatment failed to lead to a significant increase of dystrophin 
expression as ascertained by both immunohistochemistry and immunoblotting. 
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Fig. 4-5 Dystrophin expression in muscles from mdx mice that received gentamicin 
injections. Two exposures of the dystrophin immunoblot and the corresponding post-transfer 
Coomassie blue stained gel are shown. In lane 1, a molecular size marker was loaded (myosin, 
200 kDa). Lanes 2,3 are protein lysates of M. tibialis anterior (TA), lane 11 cardiac muscle of 
dystrophin-positive control mice (C57BL/6). Note that only 17% (lane 2) and 50% (lane 3,11) 
total protein were loaded for controls if compared to gentamicin-treated mdx mice. Lane 4-8 
are protein lysates of tibialis anterior muscles, 9 and 10 of cardiac muscle of gentamicin-
treated mdx mice (2-6 and 9 - female mdx mice; lanes 7,8,10 - male mdx mice). In muscle 
lysates of gentamicin-treated mdx mice dystrophin was not detected even when the blot was 
overexposed (panel B). 
 
 
 
 
 
62 
 
                                                                                                              Gentamicin Discussion 
DISCUSSION 
The urgent need of treatment for DMD, the in vitro proof that aminoglycoside antibiotics 
can overcome premature stop codons and an initial report that claimed substantial 
gentamicin induced dystrophin expression and improvement of muscle function in mdx 
mice led to the rapid initiation of clinical trials. Unfortunately, DMD patients treated with 
gentamicin did not show any benefit and dystrophin expression was not restored.  
 
In clinical trials, potential side-effects have to be carefully balanced with potential benefits. 
Long term use of gentamicin, as would be required for the therapy of DMD, may be 
associated with damage especially to the renal tubes (nephrotoxicity) and to the hair cells of 
the inner ear which can result in hearing loss (ototoxicity). Gentamicin also has a weak 
neuromuscular-junction-blocking activity among other less common side-effects. The exact 
cause of these effects is not known. But it seems reasonable that the same mechanisms 
which effect general translation and allow read-through in the case of the mdx point 
mutation also may promote the misreading in other proteins. This may result in detrimental 
function losses or gains in the affected proteins. Alternatively, proteins which do not fold 
properly due to alterations may form toxic aggregates. Aminoglycosides were shown to 
interfere with a number of RNA functions such as self splicing of group I introns (Von 
Ahsen and Noller, 1993) and hammerhead ribozyme cleavage (Stage et al., 1995). They can 
also destabilise plasma membranes and interfere with phosphatidylinositol mediated signal 
transduction. Mitochondria may be also involved in aminoglycoside toxicity because 
mitochondrial translation is closer related to procaryotic translation and therefore more 
vulnerable than eucaryotic translation. Because of the widespread use of and the frequent 
side-effects attempts were undertaken to reduce the toxicity of aminoglycosides. Iron 
chelators (Song et al., 1998) such as dihydoxybenzoate (DHB) and substances that reduce 
the production of reactive oxygen species (McFaddden et al., 2003) attenuated ototoxicity 
in guinea pigs which support the idea that iron and free radicals play a critical role. 
Ototoxicity was also reduced by leupeptin, a calpain inhibitor (Ding et al., 2002). The 
calpains are a family of calcium-activated proteases that participate in protein degradation 
and cell death. Hair cells could be also protected through inhibitors of the c-Jun-N-terminal 
kinase (JNK) signalling pathway (Bodmer et al., 2002). Even though these studies are still 
at a pre-clinical stage they may lead to the development of a protocol that reduces 
gentamicin induced side-effects. An alternative option to reduce the toxicity of 
aminoglycosides is to target the drug to the most affected tissue. In the case of DMD it 
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would be sufficient if the compound would reach the muscle. This may reduce damage of 
the more sensitive organs, i.e. the ear and the kidneys. Drug targeting to skeletal muscle 
may be achieved through coupling of the aminoglycoside to a compound that binds 
preferentially to muscle fibres. Similarly, drugs were targeted to the liver by coupling to 
galactose derivates (Hashida et al.,  2001; Ulrich, 2002). 
 
Even if the side-effects of gentamicin could be controlled and were tolerable, a significant 
improvement of muscle function related to the treatment needs to be shown in DMD 
patients. Initial clinical trials in DMD did not reveal functional improvement or even a 
small raise in dystrophin levels. This was in contrast to results that had been reported on 
successful gentamicin treatment in the mdx mouse (Barton-Davis et al., 1999), and a 
species-specific difference in gentamicin action was discussed. Therefore, the aim of our 
experiments was to reevaluate gentamicin treatment in vitro and in the mdx mouse model. 
 
In vitro experimentation has the advantages that it can be rapidly conducted, is ethically 
unproblematic when compared to animal or clinical trials, and that gentamicin application 
is straightforward in tissue culture. Even though a functional improvement of muscle force 
can not directly be ascertained in cultivated cells, a gentamicin induced read-through that 
results in de novo dystrophin expression should be easily detectable in mdx cells. 
Moreover, in vitro tests may allow the rapid screening of different forms and concentrations 
of aminoglycosides.  
Therefore, we generated immortalised, myogenic mdx cells that yielded reproducible 
results. Moreover, these cells can easily be differentiated to fused myotubes. Initial tests 
ascertained that in contrast to control myotubes the mdx myotubes did not produce 
dystrophin. Immortalised mdx cells were then incubated for 14 days with gentamicin from 
two different suppliers at different concentrations. At the highest concentrations gentamicin 
was clearly toxic to the cells because an inhibitory effect on myoblast division and myotube 
formation was observed. Moreover, treatment with gentamicin did not lead to significantly 
increased dystrophin expression. It should also be noted that immortalised mdx cells were 
successfully used by us to express dystrophin in other therapeutic experiments: 
Immortalised mdx cells were used in experiments in which AOs were applied to overcome 
a mutation in the dystrophin gene by splicing out the affected exon (see introduction). 
Clinical use of AOs would require an repeated administration to obtain a lasting effect. A  
refinement of this strategy could be the in situ production of antisense RNA. This would 
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require the transfer of the AOs sequences into the affected tissues. But because the AOs are 
very small (~25 bp) this might be more easily achieved than the transfer of the much longer  
dystrophin protein-constructs. In a recent study, Weis and colleagues in co-operation with 
our group proved the feasibility of this concept by demonstrating that expression of small 
antisense U7 snRNAs could restore dystrophin expression in immortalised mdx myoblasts 
(Brun et al., 2003). 
 
We then conducted gentamicin experiments in mdx mice. However, no increase in 
dystrophin expression and no improvement of muscle force was observed. Therefore, 
neither clinical trials in DMD/BMD nor our studies in mdx mice revealed a significant 
increase of dystrophin expression in skeletal or cardiac muscle in response to gentamicin 
treatment. Subtoxic doses of systemically administered gentamicin did not reveal 
therapeutic efficacy in dystrophin deficiency. This is at variance with the original positive 
report (Barton-Davis et al., 1999). A number of reasons may account for this discrepancy 
such as the chemical composition of the drug, the duration of treatment, the method of 
application, the exact sequence of the mutation, etc. (Karpati and Lochmüller, 2001). 
 
An important issue may be the composition of the gentamicin sulphate used. A given batch 
of commercially available gentamicin usually contains 3 major components (gentamicin 
C1, C1a and C2) that are structurally identical except for the different methylation patterns 
at the 6` position (Fig. 4-6).  
 
Fig. 4-6 Structure of gentamicin components. Commercially available gentamicin is a 
mixture of 3 components. The composition of the individual components varies from batch to 
batch.  
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Interestingly, the three components differ significantly in their propensity to induce 
misreading in bacterial and eukaryotic ribosomes (Loveless et al., 1984; Yoshizawa et al., 
1998). It was shown that gentamicin C2 induced the highest rate of misreading for poly (U)-
directed protein synthesis (Loveless et al., 1984) while gentamicin C1 was virtually 
ineffective. The gentamicin used in our experiments contained a relative high amount of the 
C2 component (52%) and may not account for the failure of dystrophin induction. It may be 
necessary to test pure compounds for their ability to induce read-through of point 
mutations. Additionally, subtle alterations of the stereochemistry at the 6’ position of 
gentamicin may lead to drugs that combine the optimal induction of stop codon read-
through with a low overall toxicity. Alternatively, other aminoglycosides such as G-418 
and paromomyxin that were also demonstrated to induce read-through (Howard et al., 
2000) could be used.  
 
The dosage, the form of application and the duration of the gentamicin treatment may be 
critical, especially as there may be only a narrow window that allows for efficient 
dystrophin production (Barton-Davies et al., 1999). According to the original report, 
gentamicin dosage was critical and differed among female and male mdx mice (Barton-
Davies et al., 1999). However, we used the same dosage and application method as 
originally reported (Barton-Davies et al., 1999). Therefore, it appears unlikely that these 
factors are responsible for the divergent results obtained by us if compared to the 
previously reported study (Barton-Davies et al., 1999). 
 
Nevertheless, the assessment of an optimal dosage would prove a great challenge in the 
putative treatment of DMD patients, becaus of a) differences in individual sensitivity to 
gentamicin toxicity b) different drug metabolism rates and c) different point mutations (see 
below). This may necessitate long term optimisation of dosing for individual patients. This 
optimisation would be further complicated since mild improvement would be difficult to 
seize: quantification of dystrophin protein in muscles would necessitate repeated muscle 
biopsies. Criteria that do not depend on invasive methods such as improvement of muscle 
function (e.g. force) may require long time expression. Surrogate markers of muscle 
damage such as serum creatine kinase levels may not yield a realistic assessment of muscle 
function. For example, gentamicin treatment of DMD patients resulted in a decrease of the 
serum creatine kinase relative to pre-trial values, while dystrophin expression and muscle 
function were not improved (Wagner et al., 2001). 
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Effective treatment of DMD may require the long term persistence of dystrophin in affected 
muscles. In theory, dystrophin production may be strongest after single peaks of 
aminoglycoside application. Therefore, it is important to determine the half-life of the 
dystrophin protein and the duration of the protective effect. Ahmad et al. (2000) 
demonstrated in a transgenic mouse model which allowed inducible dystrophin expression, 
that dystrophin persisted for more than 6 months and was accompanied with a functional 
protection of the muscle once it was associated with the sarcolemma. These observations 
indicate that it may be possible to develop treatment regimes where short time periods of 
treatment alternate with rest periods to reduce possible side-effects. We also conclude that 
the combined 3 weeks of gentamicin treatment in our mdx trial should have been a 
sufficient time period to accumulate enough dystrophin to allow its detection.  
 
Previous studies of aminoglycoside treatment have indicated that the efficiency of read-
through depends strongly on the sequence context and on the different termination 
efficiencies of the 3 possible stop codons. This may be of particular interest because 
individual DMD patients carry different stop codons in varying parts of the dystrophin 
gene. Different stop codons have low and somewhat different rates of naturally occurring 
read-through (UGA > UAG > UAA), i.e. in the absence of a drug. Moreover, it was 
recently shown that efficiency of translation termination correlates inversely with the ability 
to allow aminoglycoside induced read-through (Howard et al., 2000). UAA is the strongest 
translation terminator and allows the lowest rate of read-through in the presence of 
gentamicin. The context of 5’ and 3’ sequences also modifies the stop codon efficiency. 
The most pronounced effect has the nucleotide immediately after the stop codon (+4) 
(Brown et al., 1990; McCaughan et al., 1995). For UGA the order of bases at +4 that 
allowed the highest read-through in in vitro assays were C > U > A ≥  G. In general, 
purines may mediate a stronger termination signal at this position than pyrimidines. 
Approximately 90% of strong house keeping genes in mammals have a purine right after 
the stop codon (Tate and Mannering, 1996). Interestingly, the naturally occurring stop 
codon read-through can reach levels that ameliorate the progression of a genetic disease 
even in the absence of aminoglycosides: a UGA stop codon mutation in the gene that 
causes cystic fibrosis (CFTR) led to a milder phenotype than other types of missense 
mutations (Cuppens et al., 1990; Cuttting et al., 1990). The same mutation allowed a read-
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through of approximately 10% in the corresponding gene of a yeast model (Fearon et al., 
1994). 
 
Even in the most positive therapeutic scenario, it can be predicted that dystrophin will not 
reach normal wt levels. Therefore, additional questions need to be answered : What are the 
maximal levels of functional dystrophin that can be expected by gentamicin treatment? 
What are the minimal levels of dystrophin that bring about functional improvement? First, 
induction of high dystrophin levels is in direct competition with the impairment of general 
protein translation and increased levels of wrongly incorporated amino acids. 
Aminoglycoside concentrations that may allow high levels of dystrophin read-through may 
therefore at the same time compromise normal translation termination. In addition, 
aminoglycosides may lead to the introduction of missense mutations that will impair the 
function of dystrophin and other proteins. 
A second limitation may be the availability of dystrophin mRNA. It has been shown that 
the dystrophin mRNA is strongly reduced in muscles of mdx mice to approximately 20% of 
control levels (Chamberlain et al., 1988). This decrease of dystrophin mRNA may be 
mediated through the nonsense-mediated mRNA decay pathway which degrades 
specifically messages containing premature stop codons (Hentze and Kulozik, 1999; 
Frischmeyer and Dietz, 1999; Byers, 2002). Therefore, low levels of the prerequisite 
dystrophin mRNA may also reduce maximal translational read-through. It should be noted 
though that low-levels of aminoglycoside induced read-through may on the other hand be 
sufficient to reduce the level of nonsense-mediated decay which may result in elevated 
dystrophin mRNA levels. An example for the latter possibility has been described: read-
trough of a UGA stop codon, induced by selenocystein incorporation reduced nonsense-
mediated mRNA decay of the selenium-dependent glutathione peroxidase I gene (Moriarty 
et al., 1998). 
 
When gentamicin was not effective in the clinical trials it seemed possible that differences 
between humans and mice were responsible. Since our experiments in mice do not show a 
positive effect of gentamicin treatment in mice, the difference between species is probably 
not a key factor. The data that were represented in this study clearly indicate that additional 
tissue culture and in vivo mouse experimentation is required to identify factors or 
circumstances that may render AG effective in treating DMD/BMD. While gentamicin thus 
far did not show efficacy in DMD, the recent clinical trials yielded several useful data: 1. 
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new methodology has been developed to identify nonsense mutations in dystrophin-
deficient patients, not only large-scale deletions (Dolinsky et al., 2002; Mendell et al., 
2001); 2. an awareness was raised that different molecular defects of the same gene in the 
same disease may require different modalities of molecular treatments ; and therefore 3. 
molecular treatment may need to be custom-tailored for individual patients (Dubowitz, 
2002; Walter and Lochmüller, 2001).  
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ABBREVIATIONS 
°C  degrees Celsius 
AAV  adeno-associated-virus 
AG  amino glycoside 
APC  antigen presenting cell 
AO  antisense ologonucleotides 
Ad  adenovirus 
Ads   adenoviruses 
BMD  Becker muscular dystrophy 
bp  base pair 
CAR  coxsackie adenovirus receptor 
cDNA  complementary (to mRNA) DNA 
CFTR  cystic fibrosis transmembrane regulator 
CMV  cytomegalovirus promoter 
COOM Coomassie 
CSA   cross sectional area 
DAPC  dystrophin-associated protein complex 
DHB   dihydoxybenzoate 
Dia  diaphragm 
DMD  Duchenne muscular dystrophy 
DNA  deoxyribonucleic acid 
Dys  dystrophin 
EDL  M. extensor digitorum longus 
EDTA  ethylendiamintetraacetate 
EF-hand intracellular calcium binding motif  
e.g.  exempli gratia (Lat. = for instance)   
et al.  et alii (Lat. = and others) 
FCS  fetal calf serum 
Fig.   figure 
GRMD golden retriever muscular dystrophy 
g  gram 
HEPES N-(2-Hydroxyethyl)-piperazine-N´-2-ethansulfonacid 
HFMD  hypertrophic feline muscular dystrophy  
HSV   herpes simplex virus 
Hz  Herz 
i.e.   id est (Lat. = that is to say) 
IgG  immunoglobulin G 
INF-γ    interferon-gamma 
JNK  c-Jun-N-terminal kinase 
kb  kilo (103) bases 
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kDa  kilodalton 
l  liter 
Lo  optimal muscle length 
M  molar 
M.  musculus 
Mb  mega (106) bases  
MCK  muscle creatine kinase 
MEF2  muscle enhancer factor 2 
mdx  murine dystrophy X-linked  
MHC  major histocompatibility complex 
min  minute 
mRNA messenger RNA 
N  newton 
nNOS  neuronal nitric oxide synthase  
NCAM neuronal cell adhesion molecule 
nt  nucleotide 
NADH nicotineamide adenine dinucleotid  
pA    poly-A signal 
PBS  phosphate buffered saline 
PCR   polymerase chain reaction 
PPR  proximal promoter region 
QU  M. quadriceps 
RF  release factor 
RNA  ribonucleic acid 
RSV  rous sarcoma virus 
s  second 
SD  standart deviation 
s.e.m.  standart error 
Sol  M. soleus 
SV40  Simian virus 40 
TA  M. tibialis anterior 
tg  transgenic 
tRNA  transfer RNA 
v/v  volume per volume 
w/v   weight per volume 
WB   western blot 
wt  wild-type 
WW domain domain that contains 2 conserved tryptophans and binds proline rich proteins 
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